Index

résumés at the end of each chapter. Aβ cutaneous afferents conduction velocity, 77, 400, 418 electrical threshold, 400, 418 RII reflex, 414 skin stimulation mimicking mixed nerve stimulation, 77, 85, 204, 253, 299 tactile sensation, 391, 400 abdominal skin reflexes afferent pathway, 400 central pathway, 395, 400 convergence of tactile and noxious afferents, 402 functional organisation, 402 habituation, 394, 395 methodology, 394 normal descending facilitation, 433 protective function, 399, 401-2 reciprocal organisation, 402 spatial/temporal summation, 394 voluntary contraction, 412 upper motoneurone lesions, 433 acetylcholine neuromuscular junction, 151 recurrent collaterals, 151, 152 activity-dependent hyperpolarisation of Ia afferents, 12-13, 341 Aδ cutaneous afferents conduction velocity, 400 electrical threshold, 400 pain sensation, 391, 399-400 RIII reflex, 399-400 afferent conduction times used to suggest heteronymous Ia excitation, 70-2 Ib inhibition, 253-5

No references are given here to the mention of a topic in the

602 Index

afferent feedback accompanying a movement, 515-16 cutaneous, 388, 516 joint, 272, 516 Ia –group II, 133–5, 136, 515–16 Ib, 267-8, 516 state-dependent modulation of sensory feedback, 530 afferent fibres, see cutaneous, FRA, group Ia, group Ib group II, joint afferents afterhyperpolarisation (AHP) of motoneurones on-going EMG, 28 paired H reflex technique, 156, 157-9, 161, 178 PSTHs, 31, 32, 34, 37, 257 spatial facilitation, 47 unitary H reflex, 39 alpha (α) motoneurone α axon, motor threshold (1 × MT), 6, 7 final common path, 1 alpha motoneurone excitability methodology, 561-3 studies in patients Parkinson's disease, 584-6 spasticity, 560-3 spinal spasticity, 580 stroke, 576 alpha motoneurone, excitation through cervical propriospinal neurones, 460-3 early cutaneous reflexes, 427-30 group II interneurones: heteronymous, 304-5 homonymous, 304 lumbar propriospinal neurones, 494-6 monosynaptic Ia connections: heteronymous, 81-6; homonymous, 79 Ib excitatory interneurones, 258 transcortical cutaneous pathways, 421-4, 430-2 transcortical Ia pathways, 90-2, 548-9 withdrawal reflexes, 399-414 alpha motoneurone, inhibition through cutaneous non-noxious spinal reflexes, 429 non-reciprocal group I inhibition (wrist), 211-14, 522-4 Ib inhibition (hinge joint), 256-8 reciprocal Ia inhibition, 211 recurrent inhibition, 169-71: heteronymous, 169-70; homonymous, 169 withdrawal reflexes, 405 alpha motoneurones, recruitment order cervical propriospinal excitation, 471 corticospinal excitation through cervical propriospinal neurones, 471, 519 cutaneomuscular responses, 424-7, 519

F wave, 22 H reflex, 4 MEP: at rest, 45; during contraction, 44-5 monosynaptic Ia excitation, 3-4, 79-81 exceptions, 79, 81 reversed by presynaptic inhibition, 347-8; functional implications, 348 most reflex actions, 4 slowing eccentric contractions, 519 voluntary contraction (EMG), 25, 518 alpha-gamma co-activation, see servo-assistance alpha-gamma linkage in reciprocal Ia inhibition postulated from connections, 201 voluntary contraction, 198, 219, 223 amyotrophic lateral sclerosis, changes in spinal pathways presynaptic inhibition of Ia terminals, 369 recurrent inhibition, 184, 186, 581 anaesthetic blockade Að afferents, responsible for the RIII reflex, 393, 400 cutaneous afferents, group II excitation, 317, 318 γ efferents, 119; principle, 118-19 group I afferents natural reciprocal inhibition, 217 non-reciprocal group I inhibition (wrist), 525 presynaptic inhibition, 220, 361 reciprocal Ia inhibition, 220 unloading during walking, 315, 316 ankle and hip strategies in bipedal stance, 542 ascending projections Aß cutaneous afferents, 421, 549 Aδ cutaneous afferents, 411 cervical propriospinal neurones, 454, 479, 531 feedback inhibitory interneurones to cervical propriospinal neurones, 454 FRA. 388 group Ia afferents, 90-2, 548 motor learning, 530-1 Ib interneurones, 246-7 Renshaw cells, 154 Ashworth score, 573 autogenetic inhibition, 244, see group Ib inhibition from homonymous muscle, 244; from extensors, 246 not responsible for the clasp-knife phenomenon, 244-5 Babinski response, 433-4 dysfunction of the upper motor neurone, 434 extensor hallucis longus, 402, 403, 434

late Babinski response after spinal transection, 433

methodology, 392, 402, 434

Index 603

normal plantar response, 402-3, 404 pathophysiology, 434 disinhibition of withdrawal reflex, 434 suppression of normal response, 433, 434 background from animal experiments cervical propriospinal pathways, 452-5 cutaneous reflexes, 385-91 FRA reflex pathways, 388-91 low-threshold-induced cutaneous reflexes, 385-7 withdrawal reflexes, 387 group Ib pathways, 244-8 group II pathways, 288-93 lumbar propriospinal pathways, 490-1 monosynaptic Ia excitation, 64-6 muscle spindles and fusimotor drive, 113-17 post-activation depression, 96 presynaptic inhibition of Ia terminals, 337-40 reciprocal Ia inhibition, 197-201 recurrent inhibition, 151-4 bag intrafusal fibres, 114 bag1 fibres, 114, 115, 117 bag₂ fibres, 114, 115, 289 ball joint, see organisation of spinal circuitry at wrist level ballistic contraction, recurrent inhibition, 176 beta (β, skeleto-fusimotor) efferents, 117 background from animal experiments, 115, 117: dynamic, 117: static, 117 evidence in humans, 117 beta(β) motoneurones, 117 bidirectional connections monosynaptic Ia excitation, 73, 74 non-reciprocal group I inhibition (wrist), 205, 206 Ib excitation, 258 reciprocal Ia inhibition, 205 bi-triphasic effects cutaneous responses to non-noxious stimuli bi-triphasic effects in the lower limb, 415 triphasic effects in the upper limb, 415 disynaptic reciprocal inhibition-presynaptic inhibition, 343 - 4group I-group II excitations, 293, 297, 301 non-reciprocal group I inhibition-Ib excitation (wrist), 258 Ia excitation-Ib inhibition, 249, 253, 255-6, 257 Ia excitation-recurrent inhibition, 35, 163, 164, 166-7, 168-9, 170 reciprocal Ia inhibition-Ib excitation, 255, 258 blockade of one mechanism controlling the stretch reflex, 560 botulinum toxin, 556, 559 braking an eccentric contraction, 521

central delay in spinal pathways cervical propriospinal excitation, 457, 458, 459 cutaneomuscular spinal responses, 419 feedback inhibition of cervical propriospinal neurones, 458-9,464 group II excitation, 303 lumbar propriospinal excitation, 491-2, 493 monosynaptic Ia excitation: homonymous, 66-7, 70; heteronymous, 73 non-reciprocal group I inhibition (wrist), 205, 206 Ib excitation, 255 Ib inhibition, 253-5 presynaptic inhibition, 339; D1 inhibition, 343, 344 reciprocal Ia inhibition, 205 recurrent inhibition, 166, 171, 206 transcortical cutaneous responses, 421-3 withdrawal (early) responses, 400-1 withdrawal (late) responses in normal subjects, 410 patients with spinal transection, 408 central delay inferred from afferent conduction times cutaneomuscular spinal responses, 419 heteronymous monosynaptic Ia excitation, 70-2 Ib inhibition, 253-5 reciprocal Ia inhibition, 205 bidirectional connections heteronymous monosynaptic Ia excitation, 73 non-reciprocal group I inhibition (wrist), 205, 206 reciprocal Ia inhibition, 205 delay with respect to monosynaptic Ia excitation cervical propriospinal excitation, 459 lumbar propriospinal excitation, 493 group II excitation, 303 Ib inhibition, 253-5 recurrent inhibition, 166 delay with respect to reciprocal Ia inhibition Ib excitation, 255 presynaptic inhibition of Ia terminals, 344 cerebral palsy contribution of spasticity to motor impairment, 559, 574 reciprocal Ia excitation, 233, 579 reciprocal Ia inhibition, 233, 579 recurrent inhibition, 187 cervical propriospinal relay, background from animal experiments, 452-5 conflicting results in the monkey, 454-5

604 Index

cervical propriospinal relay (cont.) disclosure with strychnine, 455 evidence for a functional propriospinal system, 455 connections in the cat, 453, 452-3, 454 ascending projections, 454; efference copy, 454 excitatory convergence, 452: from descending tracts, 453; from peripheral afferents, 453 diverging projections, 453: on motoneurones, 453; Ia interneurones, 453 inhibitory connections, 453-4: feedback, 454; feedforward, 453; inhibitory propriospinal neurones, 453 function, 454 co-ordinated synergies, 453, 529 target-reaching, 454 updating, 454, 529 phylogenetic differences, 455, 479 cervical propriospinal relay, methodology, 455-60 critique of the tests, 457-8, 459 cutaneous suppression, 458-9 evidence for propriospinally mediated effect normative values: MEP, 459, 474; ongoing EMG, 459 stimulation and recording, 458, 481: single shocks and trains, 481; stimulus graded with respect to motor response, 458, 481; window of analysis, 458-9 suppression of the MEP, 459, 473 suppression of the on-going EMG, 458-9, 471-2, 473 underlying principles, 458, 471 evidence for propriospinally mediated effect cutaneous suppression: central delay, 458, 471, 472; disfacilitation, 459, 471-3 group I excitation, 455, 474: central delay, 457, 459; diffuse pattern of input, 457, 460; disappearance when stimulation is increased, 457, 464, 467; low threshold, 457, 460 lesion at C6-C7 spinal level, 479-81 rostral location of the relevant neurones, 459-60: corticospinal excitation, 463; corticospinal inhibition, 467; cutaneous suppression, 459, 464, 473; group I excitation, 458, 459 group I excitation, facilitation of, 455-8: H reflex, 457, 472; MEP, 456, 457; on-going EMG, 456, 457; PSTHs, 456, 457 how to disclose propriospinally mediated corticospinal excitation, 468 cervical propriospinal relay, organisation, 460-71 afferent excitatory input, 460-1 afferents responsible: group I, 460; including Ia, 460; cutaneous, 460

low threshold, 460 weakness, 460-1 widespread sources, 457, 460, 461 corticospinal excitation, 461-2, 463 initial sparing, 462, 463 peripheral inhibition, 463 rostral location, 463 spatial facilitation: PSTH, 461-3; reflex, 463 divergence, 469, 476, 529 excitatory convergence, 469 corticospinal and afferent inputs, 460, 461, 469 different afferent inputs, 469 feedback inhibition of propriospinal neurones, 463-7 afferent projections, 464: group I, 464, 465; cutaneous, 464, 465 corticospinal projections, 464-6, 467 interactions between excitatory and inhibitory inputs, 467-8 corticospinal, 467; peripheral, 461, 467 explanation for the conflicting conclusions in primates, 467-8 natural vs. artificial stimulation of the system, 468 lack of projections to motoneurones of intrinsic hand muscles, 460 organisation in subsets, 468-9 projections to motoneurones of different muscles: distal, 460, 522; proximal, 460, 516-17, 521-2 types, 469-71: corticospinal excitation, 469-71; propriospinal neurones, 470, 471 cervical propriospinal relay, physiological implications, transmission of the descending command, 471-9 cutaneous disfacilitation of the descending command, 471-4, 472 evidence for: ECR, 471-3; other motor nuclei, 473-4 quantitative contribution, 474 facilitation of propriospinal neurones, 474-6 evidence for, 475 focused descending drive, 476 onset of contraction, 472, 474-5 tonic contraction, 476-7 cervical propriospinal relay, possible function, 476-9 integration of peripheral and descending inputs, 477-8 control of force and speed of movement, 477, 518 integration at premotoneuronal level, 471 safety factor to transmission of command, 477 servo-assistance and diffuse distribution, 477, 516-17 synergies through the propriospinal system, 476, 529 motor learning, 479, 531 movements in which the system might be involved, 479 co-contraction of antagonists, 533

wore information

Index 605

expanded repertoire, 479 multi-joint movements, 476, 478, 529 rapid movements, 477, 479 reaching, 529-30 selectivity of movement focus of descending drive, 476 lateral inhibition, 477, 517 termination of movement, 475, 478, 518 tonic contraction, 476-7 cervical propriospinal relay, studies in patients, 479-85 C6-C7 lesion, 479-81: peripheral modulation of MEPs, 479-80, 481; recovery, 481 Parkinson's disease, 484-5 asymmetry of cutaneous suppression of on-going EMG, 484 compensatory mechanism, 485, 592 increased transmission of the descending command, 485, 591 methodology, 484 stroke, 481-4, 579 asymmetry of cutaneous suppression of on-going EMG, 481-3; disfacilitation, 483 changes throughout recovery, 482, 484 increased transmission of the descending command, 483, 579 methodology, 481 spasticity, 579 synkinetic contractions, 484, 579 underlying mechanisms, 483-4, 579 chain intrafusal fibres, 114, 115, 117, 289 changes in the recruitment gain of the H reflex, see recruitment gain clasp-knife phenomenon characteristics, 558 differences from the lengthening reaction, 244 responsible afferents absence of involvement of muscle group II pathways, 326 FRA, 244, 245, 326 clenching, synergy between ECR and finger flexors, 211-12, 525 clonidine, see group II excitation in spinal spasticity clonus α - γ co-activation, 139–40 characteristics, 558 co-contraction, see voluntary co-contraction coherence analysis of EMG/EMG or EEG/EMG signals, 48-9 coherence techniques, 48-9 cross-correlation, 48 use during movement, 512 concentric contractions muscle spindle afferent discharge, 135

Ib afferent discharge, 267-8 reciprocal inhibition, 222-3, 519 servo-assistance through α - γ coactivation, 516 cervical propriospinal neurones, 477, 516-17 conduction velocity AB cutaneous afferents, 77, 400, 418 Aδ cutaneous afferents, 400 group Ia afferents, 36, 64, 72, 118, 302-3 group Ib afferents, 245 group II afferents, 302-3 group II/Ia ratio, 303 contamination of the H reflex by Ib inhibition, 14-16, 67, 81 curtailment of Ia EPSPs, 14 evidence for Ib inhibition in quadriceps, 14-15 limitation of the H reflex, 14-16, 301-2, 310-12, 493, 500 convergence cervical propriospinal neurones corticospinal and group I inputs, 461-3 various peripheral afferents, 469 feedback inhibitory interneurones to cervical propriospinal neurones corticospinal and cutaneous inputs, 478, 483 corticospinal and group I inputs, 464-7 cutaneous and group I afferents, 469 feedback inhibitory interneurones to lumbar propriospinal neurones corticospinal and group I inputs, 310, 500 corticospinal and group II inputs, 310 group I inhibitory interneurones (wrist), 212 group I inputs from antagonist and homonymous muscles, 212 group I inputs from elbow and antagonist muscles, 212 group II interneurones corticospinal and group II inputs, 46-7, 307-9 group I and group II inputs, 305-6 other FRA afferents, 388, 514 interneurones mediating cutaneous reflexes A β and A δ cutaneous afferents, 402, 405 lumbar propriospinal neurones corticospinal and peripheral inputs, 46-7, 307-9, 498 group I and group II inputs, 305-6 group I from different muscles, 47, 496 Ia interneurones excitation: Ia and corticospinal, 216; Ia and cutaneous, 214-15; Ia and vestibulospinal inputs, 216-17 inhibition from Renshaw cells, 171-3, 205-8 Ib interneurones

nore information

606 Index

convergence (<i>cont.</i>),
first- and last-order interneurones, 267
multiple inputs, 265–7: from different muscles, 257–8; Ib
and corticospinal, 265; cutaneous, 261–3; joint, 263–5;
nociceptive, 265; Ia, 260–1; vestibulospinal, 265
various states: rest, 267; strong contractions, 265; weak
contractions, 265–7
PAD interneurones on Ia terminals
depression: corticospinal, 353; cutaneous, 350
facilitation: corticospinal, 353; group I, 348–50;
vestibulospinal, 353
Renshaw cells
excitation: reticulospinal, 186
inhibition: corticospinal, 172, 173
spinal interneurones, 511
cooling
evidence for group II excitation, 294, 297–9, 316, 317,
318
evidence for transcortical Ia pathway, 91
underlying principle, 297
co-ordinated activation of various synergies
cervical propriospinal neurones
multi-joint movements, 476, 478, 529
reaching, 529–30
FRA hypothesis, 389, 513, 514, 529
hierarchical control schema, 527, 529–30
motor learning, 530–1
efference copy, 479, 531
fusimotor drive, 137, 138, 530
projections to ascending tracts, 530–1
spinal heteronymous connections, 527, 528–9
group II, 304–5, 512, 529, 538; flexible synergies, 529
Ia, 63, 93–4, 512, 528, 538, 550; flexible synergies, 94, 529;
relaxation of antagonists, 528
state-dependent modulation of sensory feedback, 530
cortical stimulation, general features
advantages, 45
comparison of responses to electrical and magnetic
stimulation, 44, 424, 430–2 initial studies, 40
input–output relationship, 44
limitations, 44–5
mono- and non-monosynaptic transmission, 40
multiple descending volleys, 40–1, 309: D wave, 40, 43, 498; I
waves, 40–1, 43, 44, 498
projection to motoneurones of different type: at rest, 45, 471
during contraction, 44–5
TMS-induced responses: lower limb, 43–4; upper limb,
43

trans-synaptic activation of pyramidal tract neurones by TMS, 43 cortical stimulation, methodology coils, 42-3 cross-talk, 39-40, 44 electrical stimulation, 40 modulation of PSTHs, 40, 41, 42 motor evoked potential (MEP), 39, 41, 42 recording, 39-40 stability of the coil, 44 transcranial magnetic stimulation (TMS), 42-3, 44 cortical stimulation used for demonstration of non-monosynaptic transmission of the cortical command, 44, 307-9, 461-3, 498-500 presynaptic inhibition of Ia terminals, 44, 342, 343-4 transcortical cutaneous pathways, 424, 430-2 investigation of corticospinal projections on spinal pathways, 44 excitability of corticospinal neurones, 44 corticofugal syndrome, 557 corticospinal control, background from animal experiments α motoneurones (monosynaptic), 452, 454–5 cervical propriospinal neurones, 452, 454-5 cutaneous (private) pathways, 388 feedback inhibitory interneurones to cervical propriospinal neurones, 454, 455 γ motoneurones, 114 group II interneurones, 292 lumbar propriospinal neurones, 491 Ia interneurones, 200 Ib interneurones, 248 PAD interneurones on Ia terminals, 339 PAD interneurones on Ib terminals, 248 Renshaw cells, 153 corticospinal projections α motoneurones contralateral (monosynaptic), 40, 42, 463; possible function, 479 ipsilateral, 579 cervical propriospinal neurones, 461-3 feedback inhibitory interneurones to cervical propriospinal neurones, 464-7 feedback inhibitory interneurones to lumbar propriospinal neurones, 310, 500 γ and β motoneurones, 130 group II interneurones, 46-7, 307-9 Ia interneurones, 216 Ib interneurones, 265; tonic, 577

more information

Index	60	7
-------	----	---

lumbar propriospinal neurones, 46-7, 307-9, 498-500 non-reciprocal group I interneurones (wrist), 524 PAD interneurones on Ia terminals, 350-3; tonic, 370, 576 PAD interneurones on Ib terminals, 270 Renshaw cells, 173 cremasteric reflexes, 433 critical firing stimulus, see unitary H reflex, 38-9 critique of tests α motoneurone excitability, 563 cervical propriospinal excitation, 457-8, 459 cutaneous reflexes, 396-8 fusimotor drive, 118, 119, 126 group II excitation, 299-302 lumbar propriospinal excitation, 492-3, 500 monosynaptic Ia excitation: heteronymous, 70, 72-3; homonymous, 70 Ib inhibition, 255-6 presynaptic inhibition of Ia terminals, 340, 344-5, 346; vibration of the homonymous tendon, 341, 368, 371, 565 reciprocal Ia inhibition, 208-9 recurrent inhibition: heteronymous, 168-9; homonymous, 160 - 1cross-talk H reflex, 6 MEP, 39-40 cumulative sum (CUSUM), 33-4 cutaneomuscular responses, see cutaneous non-noxious spinal reflexes, transcortical cutaneous pathways cutaneous control of proprioceptive pathways activation of cutaneous receptors during movement, 388, 516 cervical propriospinal neurones excitation, 460, 469 inhibition, 478, 518 γ motoneurones, 127–30, 138 group II interneurones, 291, 306-7 lumbar propriospinal neurones, 496 Ia interneurones, 214-15 Ib inhibitory interneurones nociceptive, 265 tactile, 261-3: facilitation, 262; inhibition, 261-2 PAD interneurones late FRA, 408 tactile afferents, 350 spinal pathways, 384, 385, 391 cutaneous non-noxious spinal reflexes afferent pathway, 418

central pathway, 418-21 oligosynaptic, 419, 427 private, 419-21: cutaneomuscular responses, 420; RII, 419 spinal, 418-19: cutaneomuscular responses, 419; monosynaptic reflex modulation, 419; RII, 418-19 E1 cutaneomuscular excitation in the upper limb, 417 distribution, 415, 427 functional implications, 428, 514 latency, 415 maturation, 423, 428 task-related changes, 427, 428 threshold, 415 early cutaneomuscular effects in the lower limb, 429 distribution, 415: E1 excitation, 415, 416, 429; inhibition, 416 429 functional implications, 430, 514 task-related changes, 429-30 threshold, 415 monosynaptic reflex modulation, 415-18 FCR, 415-18: pattern, 415-16; underlying mechanisms, 416 - 18lower limb, 397, 415, 419 projections to motoneurones of different type, 424-7 change in the recruitment gain, 425 effects of natural stimuli, 425, 426 effects on: H reflex, 425, 426; single units, 424-5, 426 functional implications, 425-7: grip, 425-7, 519, 534-5; locomotion, 427 RII reflexes at rest, 414 biceps femoris, 414 other muscles, 396, 417 cutaneous reflexes at rest, see placing reaction, RII, RIII reflexes cutaneous reflexes, background from animal experiments, 385-91 FRA pathways, 388-91: early, 389-90; late, 390-1 initial findings, 385 modulation of the descending command, 388 private pathways of non-noxious reflexes, 385-7 corticospinal facilitation, 388 descending control, 388 forelimb, 387 stumbling reaction in locomotion, 387 toe extensor reflex, 385-7 projections to motoneurones of different type, 387 descending facilitation, 388

withdrawal reflexes, 387

608 Index

cutaneous reflexes, methodology, 391–9
critique of tests, 396–8
encroachment upon other afferents, 398, 435
recordings: at rest, 398, 414; monosynaptic reflexes, 398,
418; on-going EMG, 398, 415; PSTHs, 398
stimuli: electrical, 398; mechanical, 396; radiant heat,
396–8
evidence for spinal reflexes
non-noxious reflexes, 418-19
withdrawal reflexes: early, 400–1; late, 407
habituation, 391: abdominal skin reflexes, 394; RII reflex, 394;
withdrawal reflexes, 394
modulation of motoneurone excitability, 396
monosynaptic reflexes, 396
on-going EMG, 396, 404, 414–15
PSTHs, 396, 417
spike-triggered averaging of EMG, 396, 417
responses at rest, 394–6
RII, 394
RIII, 394; other withdrawal reflexes, 394
spatial and/or temporal summation required, 391, 392, 394,
396
stimuli, 391–4
cutaneomuscular responses, 392, 415
electrical, 391-2: on: nerves, 391-2; skin, 392; single shocks
vs. trains, 392
mechanical, 392–4: abdominal reflexes, 394; plantar
responses, 392; probe to indent the skin, 392
withdrawal reflexes, 392
underlying principles, 391
cutaneous reflexes, studies in patients, 432–8
complete spinal transection, 433
Babinski response, 433
from spinal shock to spasticity, 433
late withdrawal reflexes, 407–10
grasp reflex, 436
Parkinson's disease, 436–7
transcortical inhibition, 437, 589
withdrawal reflexes, 436–7, 589
peripheral neuropathies, 437
upper motoneurone lesions
abolition of normal reflexes, 433
Babinski response, 433–4
cutaneomuscular responses, 423, 436
withdrawal reflexes: lower limb, 434–5; upper limb, 435
cutaneous silent period
non-noxious stimuli
lower limb, 415, 416; spinal origin, 429
upper limb (I1), 415, 417; transcortical origin, 423

noxious stimuli afferent pathway, 401 central delay, 401 evidence for spinal pathway, 400-1 lower limb, 397, 404-5 Parkinson's disease, 436-7, 589 upper limb, 405, 406; evidence for motoneurone inhibition, 405, 406 upper motoneurone lesions, 435 cutaneous suppression of the on-going EMG through activation of cutaneous non-noxious spinal pathways, 415, 429 cutaneous transcortical pathways, 415, 423 feedback inhibitory interneurones to cervical propriospinal neurones, 464 evidence for disfacilitation, 459, 471-3 methodology, 458, 481; window of analysis, 458-9 normative values, 459 pattern, 478 Ib interneurones, 271-2, 518 withdrawal reflex pathways lower limb, 404-5 upper limb, 405 D wave after cortical stimulation, 40, 41, 43 D1 inhibition critique, 344-5, 364, 365-6 early part, assessment of presynaptic inhibition of Ia terminals, 343-4, 367, 565-6 late part: lower limb, 344; upper limb, 344, 372 D2 inhibition, 344 decerebrate rigidity common features with spasticity, 560 differences from spasticity, 560 underlying mechanisms, 560 descending control of spinal pathways normal, see cortico-, reticulo-, vestibulo-spinal control spasticity, 571 differences between spinal pathways in cervical and lumbar enlargements cutaneomuscular responses: cervical, 415, 427; lumbar, 415, 429 function of y drive: cervical, 137-8; lumbar, 137 heteronymous Ia excitation: cervical, 83-6; lumbar, 81-3 heteronymous Ib inhibition: cervical, 257; lumbar, 257 heteronymous recurrent inhibition: cervical, 167, 170-1; lumbar, 166, 169-70 PAD interneurones

corticospinal control: cervical, 353; lumbar, 350-3

More information

focus drive, 351, 359-60 stroke: cervical, 369; lumbar, 368-9 voluntary contraction, 363 propriospinal neurones cutaneous inhibition: cervical, 458-9, 471-4; lumbar, 496 peripheral excitation: cervical, 460-1; lumbar, 494-6 voluntary contraction, cervical, 471-9; lumbar, 500-2 uncertainty about extrapolations, 511 differences between spinal pathways to proximal and distal muscles, 521-2 distal muscles, 522 proximal muscles, 521-2 disfacilitation of motoneurones disfacilitation vs. inhibition, 473 feedback inhibition of cervical propriospinal neurones differences with inhibition, 416-18, 473 evidence for disfacilitation, 459, 471-3, 483 site of disfacilitation, 473 feedback inhibition of group II interneurones, 307, 310 feedback inhibition of lumbar propriospinal neurones, 307, 310, 496, 500, 502 relaxation of antagonists, 527, 528 spasticity, inhibitory pathways, 571: Ia interneurones, 232, 570; Ib interneurones, 568 suppression of on-going EMG, 25 disinhibition of motoneurones non-reciprocal group I inhibition, 214 reciprocal Ia inhibition, 222, 223, 225, 520 disynaptic effects excitation cervical propriospinal excitation, 457 lumbar propriospinal excitation, 491-2 group II excitation, 302-4 inhibition Ib inhibition, 253-5 non-reciprocal group I inhibition (wrist), 205, 206 reciprocal Ia inhibition, 205 recurrent inhibition, 166 DOPA disclosure of late FRA pathways in the spinal cat, 390 effect on group II excitation in spinal spasticity, 322 see also Parkinson's disease, 582-92 duration group II excitation, 295, 300 Ib inhibition, 155, 255

monosynaptic Ia excitation, 261 presynaptic inhibition, 338 reciprocal Ia inhibition, 26-7, 201, 203-4 recurrent inhibition, 152, 159, 166, 171, 206 dystonia effects of rTMS, 372 non-reciprocal group I inhibition (wrist), 234, 372 presynaptic inhibition of Ia terminals, 371-2 correlation with dystonia, 372 D1 inhibition, 371-2: early phase, 371-2; late phase, 372 group III-induced presynaptic inhibition, 372 specific descending control, 372 unaffected side, 372 E1, early cutaneomuscular excitation, see cutaneous non-noxious spinal reflexes E2, late cutaneomuscular excitation, see transcortical cutaneous pathways early discharge, 121, 298 eccentric contractions fusimotor drive, 135; walking, 544 reciprocal inhibition, 519 servo-assistance through α - γ coactivation, 516 cervical propriospinal neurones, 516-17 slowing contractions, 521 fusimotor drive, 521 recruitment order of motoneurones, 519 walking, 544 efference copy, 454, 479, 531 electrical stimulation afferent fibres, see threshold to electrical stimulation cutaneous reflexes, 391-2 motor cortex, 40 electrodes for recording microneurography, 119 needle: F wave, 21; PSTH, 30, 31, 37; unitary H reflex, 37 surface: F wave, 23; H reflex, 5: bipolar, 5; monopolar, 6; MEP, 39; on-going EMG, 28; PSTH:30 surface differential, PSTH, 31 wire, PSTH:31, 37 endings cutaneous mechanoreceptors, 113; activation by vibration, free nerve endings, 113 see also: Golgi tendon organs, primary endings, secondary endings

610 Index

EPSP (excitatory post-synaptic potential)
curtailment of the compound Ia EPSP of the H reflex by
oligosynaptic IPSPs:14–15
Ia EPSPs in motoneurones, 3; evoked by H and tendon reflex
afferent volleys, 118
rise time of the test Ia EPSP, 9
excitation, see α motoneurone excitation; disinhibition of
motoneurones
F wave, general features, 21–2, 24
all muscles, 22
amplitude, 23
chronodispersion, 23
interest in distal muscles, 22
latency, 23
motoneurones involved in the F wave, 22
variability and persistence, 22–3
F wave, methodology
basic methodology, underlying principles, 21–2
used as a measure of motoneurone excitability,
23-4
F wave, studies in patients
Parkinson's disease, 585
peripheral neuropathies, 24
proximal nerve lesions, 24
spasticity, 24, 562–3
fatigue, compensation for muscle fatigue
recurrent inhibition, 174, 179, 515
spindle activation, 135, 512
feedback
need for afferent feedback, 136–7
negative feedback to motoneurones, via Renshaw cells, 151
positive feedback to group II interneurones through the γ
loop, 291, 323, 325, 567–8, 581
feedback inhibition of cervical propriospinal neurones,
background from animal experiments
cat, 454: ascending projections, 454; corticospinal control, 454; function, 454
monkey, 455
phylogenetic differences, 455
feedback inhibition of cervical propriospinal neurones,
methodology
cutaneous suppression of on-going EMG and MEP, 458–9
evidence for: disfacilitation of motoneurones, 459, 471–3;
inhibition of propriospinal neurones, 458–9
feedback inhibition of cervical propriospinal neurones,
organisation
afferent input
group I, 464: heteronymous, 464; homonymous, 464, 465

cutaneous, 464: not involved in cutaneomuscular responses, 420; pattern, 465, 478 convergence: corticospinal and cutaneous inputs, 478; corticospinal and group I inputs, 464-7; cutaneous and group I inputs, 469 corticospinal excitation, 464-6, 467 initial sparing, 466 reversal when increasing the input, 464-5; underlying mechanism, 466 disfacilitation disfacilitation vs. inhibition, 416-18, 473 evidence for disfacilitation: cutaneous, 459, 464, 471-3; group I, 464 site of disfacilitation, 473 various motoneurone pools, 473-4 explanation for conflicting conclusions in primates, 467-8 interactions between excitatory and inhibitory inputs to propriospinal neurones, 467-8: corticospinal, 467; peripheral, 461, 467 projections to propriospinal neurones, 464, 467 feedback inhibition of cervical propriospinal neurones, possible function control of force and speed, 477, 518 natural vs. artificial stimulation of the system, 468 selectivity of movement, 477, 517 termination of movement, 478, 518 feedback inhibition of lumbar propriospinal neurones corticospinal excitation, 310, 500; disclosure, of connections with corticospinal facilitation, 500 group I excitation, 307, 496-7: heteronymous, 496-7; homonymous, 496 focus of the descending motor command, 502-3 feedforward inhibition of cervical propriospinal neurones cat, 453 humans, 467, 477 monkey, 455 flexible synergies through fusimotor drive, 135, 517 inhibition of group II excitation, 514, 538 lateral inhibition of cervical propriospinal neurones, 477, 517 Ib inhibition, 273, 517 presynaptic inhibition of Ia terminals, 94, 359-60, 517, 529 recurrent inhibition, 94, 183-4, 529, 538 flexion reflexes, see withdrawal reflexes flexor spasms, 140, 434-5 follow-up length servo, 114: postulated from connections, 114 force of movement, spinal mechanisms contributing to, 517 - 18

feedback inhibition of cervical propriospinal neurones, 477, 518 fusimotor drive, 135, 518 non-reciprocal group I inhibition (wrist), 524 Ib inhibition, 271, 518 dynamic control through Ia projections, 272 hinge joint movements, 517 maintenance of an operating level, 271, 515 smooth profile of force, 271, 515 tonic contractions, 515 presynaptic inhibition of Ia terminals, 358, 359, 518 reciprocal Ia inhibition, 224, 518 recurrent inhibition, 179, 518 FRA (flexion reflex afferents) characteristics, 388-9 clasp-knife phenomenon, 244 critique of the concept, 389 reasons to group FRA, 388-9 ascending projections, 388 descending control, 388-9 extensive afferent convergence, 385, 388 FRA hypothesis in movement, 386, 389, 513, 514, 529 FRA pathways in the cat (early), 389-90 alternative FRA pathways, 388-9 possible functional role, 389 presynaptic inhibition of FRA, 390 projections to spinal interneurones, 390 group II interneurones, 292 Ia interneurones, 199 Ib interneurones, 247-8 PAD interneurones, 339 Renshaw cells, 153 FRA pathways in the cat (late), 390-1 appearance with DOPA, 390 inhibition from early FRA pathways, 386, 390 inhibitory effects mediated via Ia interneurones, 390 mediated via specific interneurones, 390 mutual inhibition between flexors and extensors, 386, 390; possible role in locomotion, 390 presynaptic inhibition of Ia afferents, 390 frontal lesions dishabituation, 436 grasp reflex, 436 functional stretch reflex, 91, 539 fusimotor drive, background from animal experiments, 113-17 dynamic γ drive, 114, 115 follow-up servo length, 114 initial investigations, 113

postulated role, 114 servo assistance, 114 static y drive, 114, 115 fusimotor drive, methodology, 117-26 comparison of tendon jerk and H reflex, 9, 117 differences in several aspects, 2-3, 117-18 critique of tests, 118, 119, 126 microneurography, 119-24: basic methodology, 119-20; bias towards large axons, 123; identification of endings, 120-2; microelectrode, 119; uncertainties, 123-4 nerve blocks: anaesthetics, 119; pressure, 117, 119, 133 thixotropy, 122, 124-6: human studies, 124-5; perspectives, 126; principle, 124 fusimotor drive, organisation, 127-30 background fusimotor drive, 127: dynamic, 127; static, 127, 128 corticospinal projections to γ and β motoneurones, 130 cutaneous projections to γ motoneurones lower limb in: reclining, 127-8; standing, 128, 129 possible involvement in late cutaneomuscular responses, 420 upper limb, 129-30 fusimotor drive, receptor-bearing muscle contraction, 133-6 activation of: $\beta,$ 136; $\gamma_d,$ 136; $\gamma_s,$ 136 appearance of spindle discharge after the EMG, 125, 133 co-contraction of antagonists, 135, 532 concentric and eccentric contractions, 135 contraction of antagonists, 135 contribution to excitation of α motoneurones in, 133–5 hinge joint movements, 135, 521 tonic contraction, 117, 122, 133, 512 decline of spindle activity during long-lasting contractions, 125.135 excitation of synergist motoneurones through heteronymous Ia and group II connections, 93-4, 512, 528-9,550 focus on contracting muscles, 122, 135, 517 force-related, 135, 518 FRA hypothesis, 389, 513, 514 muscle fatigue, 135, 512 mutual reinforcing of Ia and group II excitations, 512-14 persistence of spindle discharge after EMG disappearance, 122, 124, 125 primary and secondary endings, 135, 512 reciprocal Ia inhibition, 221-3, 519 spindle activity during standing, 135, 537-8; cutaneous control, 128 stretched antagonistic muscles, 135

612 Index

fusimotor drive, receptor-bearing muscle contraction, possible function, 136-8 co-contraction, 138 cutaneous control, 138 need for afferent feedback, 136-7 separate control of γ_s and γ_d motoneurones, 138 slowing eccentric contractions, 521 fusimotor drive, remote contractions (Jendrassik manoeuvre), 131 - 3fusimotor drive, servo-assistance motor learning, 137, 138, 530 through α - γ coactivation, 516 cervical propriospinal neurones, 477, 516-17 unstable stance, 537-8 voluntary co-contractions of antagonists, 135, 532 voluntary movement, 135, 516 lower limb, 137 upper limb: distal muscles, 137-8, 522; proximal muscles, 521 - 2voluntary tonic contraction, 512-14 walking, 544 fusimotor drive, studies in patients, 138-41 Parkinson's disease, 140-1, 586 indirect evidence, 586 insufficient data, 586 microneurography, 586 rigidity, 140-1 tremor, 141 spasticity, 139-40, 563-5 animal models, 564 clonus, 139-40 flawed arguments for, 139, 564 how it could produce spasticity, 563 importance of contribution, 564-5 microneurography, 139, 564 possibility of occurrence, 139, 564-65 reciprocal Ia inhibition, 574 spinal spasticity, 140, 580 positive feedback through group II projections, 140, 325, 580 reflex activation of γ motoneurones, 140, 580 stroke, 139-40 contribution to motor deficit, 139, 140, 565 γ activity, 139, 576 GABA, 337

gain hypothesis, see recurrent inhibition, 179 gait, see running, walking gamma (γ) drive, see fusimotor drive gamma efferents and motoneurones background from animal experiments, 114: γ_d , 114; γ_s , 114 background γ drive, 127: dynamic, 127; static, 127 corticospinal projections, 130 cutaneous projections lower limb: reclining, 127-8; standing, 128 upper limb, 129-30 possible role of positive γ feedback, 291, 325 glycine, 198-9, 214, 233 Golgi tendon organs background from animal experiments, 245 origin of Ib afferents, 113, 245 sensitivity to vibration: cat, 245; humans, 123, 130-1, 245 voluntary contraction, 267-8 grasp reflex, 436 group I input to cervical propriospinal neurones, 460 feedback inhibitory interneurones to cervical propriospinal neurones, 464 feedback inhibitory interneurones to lumbar propriospinal neurones, 307, 496-7 group Ib excitatory interneurones, 255, 258 group Ib inhibitory interneurones, 252-3, 256-8 group II interneurones, 291, 305-6 lumbar propriospinal neurones, 305-6, 494 non-reciprocal group I inhibitory interneurones (wrist), 212 Ia interneurones, 204-5 PAD interneurones, 348-50 group Ia afferents background from animal experiments, 64 conduction velocity, 36, 64, 72, 118, 303 electrical threshold, 64, 67-9, 75, 204, 303 activity-dependent hyperpolarisation, 12-13, 341 elevation by tendon vibration, 76, 205, 245, 260-1 in the inferior soleus nerve, 69 large range in human experiments, 77-8; underestimation of Ia effects, 78 with respect to motor threshold, 81 excitability cycle, 11 monosynaptic projections on motoneurones, 66-77 motoneurones of different type, 79-81 presynaptic inhibition, 347-8 projections on interneurones cervical propriospinal neurones, 460 lumbar propriospinal neurones, 494 group II interneurones, 305-6 Ia interneurones, 204-5 Ib inhibitory interneurones, 260-1

wore information

non-reciprocal group I interneurones (wrist), 212 PAD interneurones, 350 see also transcortical Ia pathways group Ib afferents conduction velocity, 245 electrical threshold close to that of Ia afferents, 245 use of vibration to distinguish between Ia and Ib afferents: cat, 245; humans, 251, 260-1 projections on interneurones cervical propriospinal neurones, 460 lumbar propriospinal neurones, 494 non-reciprocal group I (wrist), 212 Ib excitatory, 255, 258 Ib inhibitory, 252-3, 256-8 PAD interneurones, 350 group Ib excitation background from animal experiments: trisynaptic excitation of flexor motoneurones, 246 connections and organisation cutaneous facilitation, 259, 262 not involved in the peroneal excitation of quadriceps motoneurones, 258-60, 493 only found between strict antagonists, 258: lower limb, 250, 258; upper limb, 251, 258 methodology, 255: electrical threshold, 258; latency, 255; tendon tap, 251, 255 studies in spastic patients, 277-9, 569 contribution to adverse co-contraction of the antagonist, 279.575 contribution to spasticity, 278-9, 569 evidence for increased Ib excitation, 230, 277-8 spinal cord injury, 277, 581 stroke, 277, 577 underlying mechanisms, 278, 577, 581 group Ib inhibition (hinge joint), background from animal experiments, 244-8 contraction-induced Ib inhibition, 248 general features of Ib pathways, 245-6 absence of inhibition from Renshaw cells, 245-6 denomination, 245 reciprocal organisation, 245 Golgi tendon organs and Ib afferents, 245 initial findings, 244-5 input, extensive convergence, 247-8: descending tracts, 248; peripheral afferents, 247-8 post-activation depression, 248 presynaptic inhibition, 247, 248 projections to, 246-7

α motoneurones, 246, 247: alternative pathways, 246; dominant pattern, 246; extended pattern, 246; inverse myotatic reflex, 246 ascending tract neurones, 246-7 y motoneurones, 246 mutual inhibition of Ib interneurones, 246 reflex reversal during fictive locomotion, 248 group Ib inhibition (hinge joint), methodology critique of tests, 255-6 biphasic effects: presynaptic inhibition of Ia afferents, 255-6: underestimation, 257 electrical stimulation over tendons, 256 weakness of isolated Ib inhibition, 256 evidence for Ib inhibition, 252-5 differences from reciprocal Ia inhibition, 255 disynaptic inhibition, 253-5, 261: H reflex, 253; PSTHs, 253 - 5Ib origin, 252-3: absence of cutaneous effect, 253; ischaemia, 252; low electrical threshold, 250, 252; tendon tap, 251, 252-3 short duration, 255 inhibition monosynaptic reflexes, 249: biphasic effects, 249, 250; isolated inhibition, 249, 250, 251 PSTHs, 249-51, 252 group Ib inhibition (hinge joint), organisation control by joint afferents, 263-4, 265: function of protection, 263-5; heteronymous, 263; homonymous, 263 convergence of Ia afferents, 260-1 corticospinal control, 265 cutaneous control, 261-3 facilitation, 259, 262: not involved in cutaneomuscular responses, 420; pattern, 262, 272; rest, 262; reversal during contraction, 262 inhibition, 254, 261-2: mutual inhibition of interneurones, 254, 261-2; pattern, 261 descending facilitation of first-order interneurones:262, 267, 271 multiple convergence, 265-6, 267 first- and last-order interneurones, 267 various states: rest, 267; strong contractions, 265; weak contractions, 265-7 nociceptive control, 265: cutaneous, 265; muscle, 265 organisation, pattern and strength, 256-8 convergence from different muscles, 257-8: lower limb, 257-8; upper limb, 258 divergence, 257, 258 heteronymous, 257: lower limb, 257, 260; upper limb, 257

More information

614 Index

group Ib inhibition (hinge joint), organisation (cont.) homonymous, 256-7 organisation in subsets, 257 underestimation, 257 vestibulospinal control, 265 group Ib inhibition (hinge joint), physiological tasks, 267-75 contraction of antagonistic muscles, 273, 520 contraction of synergists, 272-3; underlying mechanism, 269, 272 contraction of the target muscle, 268-71 distinct from changes in presynaptic inhibition of Ia terminals, 268-70 homonymous Ib inhibition, 268, 269; heteronymous Ib inhibition, 268, 269 onset, 269, 270 tonic, force-related, 268, 269, 515 underlying mechanisms, 268-71: descending, 270; peripheral, 270; presynaptic, 270; postsynaptic, 270 walking, 273-5 heteronymous Ib pathways to biceps femoris, 274, 275, 546 Ib pathways to extensors, 273-4; soleus, 273 group Ib inhibition (hinge joint), possible function group I inhibition of antagonists, 273, 520 Ib inhibition of active motoneurones, 271; hinge joint movements, 517; tonic contraction, 515 contribution to force, 271, 518; dynamic control, 272; maintenance of an operating level, 271, 515; smooth profile of force, 271, 515 restoration by other afferents, 271-2 termination of movement via facilitation by: cutaneous afferents, 262, 271-2, 518; joint afferents, 263, 272, 518 Ib inhibition of inactive synergists and selectivity, 273, 517 walking prevention of excessive reflex activity in soleus, 274, 546 - 7stability of the knee, 274-5, 547 group Ib inhibition (hinge joint), studies in patients, 275-7 hyperekplexia, 276 Ib inhibition vs. propriospinal excitation, 277, 568 Parkinson's disease (ankle), 276-7, 588 correlation with: rigidity, 276, 588 effect of treatment, 588 underlying mechanisms, 277, 588 spasticity (ankle), 276, 568-9 how it could produce spasticity, 568 importance of contribution, 569 methodology, 275-6, 568

spinal spasticity, 276, 277, 581 stroke, 276, 577: correlation with spasticity, 276; underlying mechanisms, 277, 577 group II afferents conduction velocity group I/group II ratio: cat, 289; humans, 303 peripheral nerves, 289, 302-3: distal, 302, 303; proximal, 302.303 within the spinal cord: cat, 289; humans, 302 electrical threshold cat, 289 group II/group I ratio: cat, 289; humans, 303 high threshold, 293, 295, 297 projections (cat) α motoneurones: monosynaptic, 289; via interneurones, 289-91 γ motoneurones: monosynaptic, 291; via group II interneurones, 291 inhibition of Renshaw cells, 153 lumbar propriospinal neurones, 289, 494 mutual inhibition of interneurones, 291 group II excitation, see also lumbar propriospinal pathways group II excitation, background from animal experiments, 288-93 excitatory input from, 290, 291-2 contralateral group II afferents, 292 descending tracts, 292 ipsilateral group II afferents, 291; convergence-divergence, 291 other peripheral afferents, 291-2 group II interneurones, 289 caudal interneurones, 289 rostral propriospinal neurones, 289 very effective transmission, 290 initial findings, 288-9 monoaminergic inhibitory control, 292 locus coeruleus, 292 projections to γ motoneurones, 292 selective control of group II transmission, 292 underlying mechanisms, 290, 292 mutual inhibition of group II interneurones, 291, 292 post-activation depression, 292-3 presynaptic inhibition, 292 feedback control, 292 feedforward control, 292 projections on a motoneurones, 290, 291 alternative pathways, 288, 291 distribution extensors-flexors, 288, 290, 291

muscle origin of inhibition, 291

More information

projections on γ motoneurones, 290, 291; positive feedback, 291 secondary endings and group II afferents, 289 group II excitation, methodology, 293-302 critique of tests, 299-302 contamination by group I effects, 14-15, 299-301 interactions at interneuronal level, 301; facilitation, 301; occlusion, 301 interactions at motoneuronal level, 301 limitation of the H reflex by Ib inhibition, 14-16, 301-2, 310-12, 493, 500 overlapping of group I and group II effects, 3, 301 stretch-induced responses in upright stance, 301 evidence against excitation due to stimulation of cutaneous afferents, 299 fusimotor or motor axons, 297, 298 joint afferents, 299 evidence for group II effects, 297-9 high threshold, 293, 295, 297, 300 pharmacological validation, 294, 299, 300 slowly conducting afferents, 297-9: cooling, 294, 297-9; height of subjects, 297, 307 facilitation of, 293-7 H reflexes, 293-5, 296 on-going EMG, 296, 297, 300 PSTHs of single units, 295-7 stretch-induced responses, 293, 294 medium-latency responses, 293 short-latency responses, 293 group II excitation, organisation, 302-10 central pathway, 303-4 central latency, 303 rostral location, 303-4 convergence of group I afferents, 305-6: delay when group I excitation is inhibited, 306; facilitation-occlusion, 296, 306; ischaemic blockade of group I afferents, 306 corticospinal facilitation of, 307-10 group II interneurones, 307-9 feedback inhibitory interneurones, 308, 309, 310 disfacilitation of motoneurones, 307; by: group I afferents, 307; group II afferents, 307 distribution, 304-5 bilateral connections, 305 heteronymous connections, 304-5: lower limb, 304-5; upper limb, 305 homonymous connections, 304 lack of evidence for cutaneous convergence, 306-7 group II excitation, physiological tasks, 310-20 postural tasks, 312-14

perturbation to stance, 312, 539: bilateral response, 294, 313; effects of the postural set, 311, 313, 541; responses in the kinematic chain, 542; underlying mechanisms, 314 unstable stance, 313-14: focus, 538; leaning backwards, 311, 313-14; leaning forwards, 314; underlying mechanisms, 314, 538 voluntary contraction of target muscles, 310-12 H reflex, contamination by Ib inhibition, 14-15, 26, 27, 301-2.310-12 quadriceps contraction, 312; underlying mechanism, 312 semitendinosus contraction, 312; underlying mechanism, 312 walking, 314-20 effects of unloading soleus, 315-16 M2 stretch responses, 316-18: heteronymous muscles, 316; tibialis anterior, 316, 317, 318, 548; triceps surae, 316-17, 318.548 peroneal group II excitation of quadriceps, 318-19, 546; underlying mechanisms, 318-19 group II excitation, possible function postural tasks, 314 perturbations to stance, 312-14, 541 unstable stance, 314, 538; focus, 538 servo-assistance convergence of Ia and group II afferents, 313, 316, 318, 319-20.512-14 FRA hypothesis, 389, 513, 514, 529 lack of post-activation depression, 310, 512-14 selectivity, 514, 529 walking contribution to soleus activation, 319-20, 545-6 stabilisation of the ankle, 318, 549 stabilisation of the knee, 319, 547 group II excitation, studies in patients, 320-6 Parkinson's disease, 326 increased group II excitation and rigidity, 326, 327, 583-4, 588 - 9perturbations to stance, 326, 589-90: functional implications, 590; influence of the postural set, 326, 327, 589-90; underlying mechanisms, 326, 590 peripheral neuropathies, 320 Charcot-Marie-Tooth disease, 320, 321 diabetic neuropathy, 320, 321 spasticity, pathophysiology, 320-6, 567-8 absence of correlations with clinical spasticity, 325 actions of monoamines, 321, 324-5, 568: group I excitation, 568; group II excitation, 568; interpretation with caution, 321-2, 325, 568; therapeutic action, 324-5, 568

Index 616

group II excitation, studies in patients (cont.)
group II pathways and clasp-knife phenomenon, 326
how it could produce spasticity, 567
importance of contribution, 324-6, 568
methodology, 320–1, 567
positive feedback via excitation of γ motoneurones, 325,
567–8
possible mechanisms underlying increased group I
excitation, 324; muscle stretch, 324: propriospinal
contribution to tendon jerk, 324
spinal spasticity, 322, 323, 581
changes in group I-group II excitation, 322
effect of: clonidine, 322, 323; DOPA, 322, 323
positive feedback via excitation of γ motoneurones, 323,
325, 567–8, 581
underlying mechanisms, 324, 581
stroke, 322, 323, 577
affected side, 322
effect of tizanidine, 322
unaffected side, 322
underlying mechanisms, 322–4, 577
group II inhibition of motoneurones
cat, 288, 291
lack of evidence in humans, 307
lack of involvement in clasp-knife phenomenon, 326
group III afferents
clasp-knife phenomenon, 326
contribution to FRAs, 388
contribution to late withdrawal reflexes, 433
high-threshold inhibition of quadriceps after tibial nerve
stimulation, 307
presynaptic inhibition of Ia terminals, 372
H reflex, general features
advantages, 21
comparisons with the tendon jerk
differences in the afferent volleys, 2–3, 117–18; at the
motoneurone pool, 118
γ drive, 9, 117
Jendrassik manoeuvre, 131–3
desynchronisation of the reflex volley, 9–10
distorting effects of normalisation, 16, 17, 219
during voluntary contraction, 4, 18, 69, 79
evidence for a two-neurone arc, 66–7
initial studies, 2
input–output relationship, 17–18
less sensitivity to inhibition than the ongoing EMG, 26–7,
203–4
limitations, 11–20
·

mechanisms acting on the afferent volley, 11-16 monosynaptic pathway, 2, 66-7 motoneurones involved, 4, 79-81 necessity of activation of many Ia afferents, 154-5 'pool problems': comparison with single unit recordings, 20, 21 principles of the method, 3, 4 recruitment gain, 18-20 size-related sensitivity of the reflex, 16-18 variant of the method, 4 H reflex, limitations due to, 11-20 alterations in the excitability of Ia afferents, 12-13 changes in the recruitment gain, 18-20, 340, 344, 346, 425 consequences of size-related sensitivity of the reflex when using conditioning effects: large, 18; modest, 18 contamination by oligosynaptic inhibition, 14-16, 37, 67, 70, 81, 301-2, 310-12, 493, 500 curtailment of Ia EPSPs, 14 evidence for Ib inhibition in quadriceps, 14-15 plateau potentials, 20 'pools problems', 16-20, 37 poor time resolution, 9-10, 70, 205, 253 post-activation depression, 13-14, 97-9 presynaptic inhibition of Ia terminals, 13, 81 size-related sensitivity of the reflex, 16-17 H reflex, methodology, 4-11 'adjusting' the test stimulus intensity, 18, 219 basic methodology, 4-11 cross-talk, 6 electrical stimulation, 6-7: bipolar, 7; monopolar, 6; percutaneous, 6 expression as a percentage of M_{max} , 6, 8 general experimental arrangement, 4; awareness, 4; posture, 4 M_{max}, 7–8 magnetic stimulation, 7, 69 measurement, 6 monitoring the stability of the stimulation, 8 muscles in which it may be recorded at rest, 4, 79 random alternation, 9 recording, 5-6 recovery cycle, 10-11, 12 recruitment curve, 5, 7; collision with the antidromic motor volley, 7; descending limb, 8 stimulus duration: electrical, 6; magnetic, 7 stimulus rate, 97-9; at rest, 7, 13-14, 97-9; during contraction, 98, 99

More information

threshold tracking, 11, 12: advantages, 11; disadvantages, 11; principle, 11 voluntary contraction, 4, 69, 79, 95 H reflex, studies in patients H_{max}/M_{max} ratio Parkinson's disease, 584-5 spasticity, 562 spinal spasticity, 580 stroke, H_{max}/M_{max} ratio: FCR, 576; soleus, 576 normative data, 20-1 peripheral neuropathies and nerve lesions, 95-6 recovery cycle Parkinson's disease, 585 spasticity, 562 reflex threshold Parkinson's disease, 585 spasticity, 562 H reflex, used to study cervical propriospinal pathways, 457, 474-5 cutaneous pathways, 396 group II pathways, 293-5 lumbar propriospinal pathways, 493 monosynaptic Ia excitation heteronymous, 70, 71 homonymous: at rest, 4, 66-7, 68, 79; during contraction, 69, 79, 80, 95 Ib inhibition, 249 presynaptic inhibition of Ia terminals, 340, 341 - 6reciprocal Ia inhibition, 201 recurrent inhibition activation of Renshaw cells, 155-7, 162 heteronymous recurrent inhibition, 161-9 homonymous recurrent inhibition, 155-61 H' test reflex, see recurrent inhibition (homonymous), methodology handedness-related symmetry-asymmetry cervical propriospinal neurones: cutaneous inhibition, 458; peripheral excitation, 476-7 H reflex, 20 habituation of cutaneous reflexes abdominal skin reflexes, 394 E1 cutaneomuscular response, 415 grasp reflex, 436 RII reflex, 394 withdrawal reflexes normal subjects, 394 Parkinson's disease, 436 upper motoneurone lesions, 434

hemiplegia, see stroke heteronymous connections, see group Ib inhibition, group II excitation, monosynaptic Ia excitation, recurrent inhibition homonymous connections, see group Ib inhibition, group II excitation, monosynaptic Ia excitation, recurrent inhibition homosynaptic depression, see post-activation depression hopping cutaneous excitation, 432 heteronymous Ia connections, 93-4, 550 short-latency Ia stretch reflex, 87-8 hyperekplexia, changes in spinal pathways Ib inhibition, 276 reciprocal Ia inhibition, 233: lower limb, 233; upper limb, 214, 233 recurrent inhibition, 187 I waves after cortical stimulation, 40-1, 43, 44 I1, cutaneomuscular inhibition, see transcortical cutaneous pathways inhibition, see a motoneurone inhibition; disfacilitation of motoneurones; presynaptic inhibition initial part of monosynaptic excitation monosynaptic transmission, 16, 67, 346, 349, 352, 362, 364 uncontaminated by interneuronal inputs cortico-motoneuronal excitation, 46, 47, 308-9, 456, 462, 463, 466, 472, 473, 498, 499 Ia excitation, 15, 212, 263, 264, 266, 267 input-output relationship H reflex, 17-18 **MEP 44** recurrent inhibition, 152 integration at premotoneuronal level cervical propriospinal neurones, 477-8 Ib interneurones, 247-8, 265-7 spinal interneurones interneuronal transmission, evidence for, see convergence, initial part of monosynaptic excitation, spatial facilitation intrafusal fibres, see bag and chain fibres ischaemic blockade Aβ cutaneous afferents effects on RIII reflexes, 393, 411-12 responses to perturbations to stance, 540 group I afferents group Ib effects, 252 Jendrassik manœuvre, 132 monosynaptic Ia excitation (homonymous), 69

nore mormation

618 Index

ischaemic blockade (cont.)
perturbations to stance, 89
post-activation depression, 97, 98; reciprocal Ia inhibition, 221
presynaptic inhibition of Ia terminals during motor tasks, 220, 358, 361
projections on group II interneurones during walking, 306, 315–16, 317, 318, 502
reciprocal Ia inhibition during motor tasks, 220, 225, 229
running, 87
inverse myotatic reflex, 246
Jendrassik manoeuvre
central changes in the gain of the reflex, 133, 134
fusimotor drive, 131; flawed hypothesis, 131–3
presynaptic inhibition of Ia terminals, 133, 361–2
reciprocal Ia inhibition, 133, 227
joint afferents
activation in extremes of movement, 272, 516
contribution to FRA, 388
facilitation of motoneurones, 264
facilitation of Ib inhibitory interneurones
evidence, 263–5
function: protection, 263–5; termination of movement, 272
518
inhibition of PAD interneurones, 339
lateral articular nerve of the knee joint, 263
projections on group II interneurones, 291
joint stiffness
co-contractions of antagonists, 533–4
quiet stance, 536–7
L-acetylcarnitine (L-Ac)
recurrent inhibition of motoneurones, 158, 159–60, 168
recurrent inhibition of Ia interneurones, 208
landing, short-latency Ia stretch reflex, 88–9
heteronymous Ia connections, 93–4, 550
quadriceps, 88–9
soleus, 88
triceps brachii, 89, 521
late spinal withdrawal reflexes, see withdrawal reflexes (late),
patients with complete spinal transection
lengthening reaction, 244
load compensation
presynaptic inhibition of Ia terminals, 359
stretch reflex during running, 87
local sign of cutaneous effects
facilitation of

Ib excitation, 259, 262, 271 Ib inhibition, 262, 272 inhibition of cervical propriospinal neurones, 478 PAD interneurones, 350 initial findings, 385 organisation of withdrawal reflexes, 402-5, 407 locomotion possible role of late FRA pathways, 390 see running, walking locus coeruleus noradrenergic control of group II pathways in the cat, 292 parkinsonian rigidity, 326, 590 perturbations to stance normal subjects, 314 Parkinson's disease, 326, 589-90 patients with hemiplegia, 322 spinal spasticity, 324, 581 lumbar propriospinal pathways, background from animal experiments, 490-1 initial findings, 490-1 dorsolateral propriospinal neurones, 491 ventromedial propriospinal neurones, 289, 491 descending control, 491; peripheral input, 491 lumbar propriospinal pathways, methodology, 491-4 critique of tests: H reflex, 14-16, 301-2, 310-12, 493, 500; PSTHs, 492-3; rostral location, 494 evidence for propriospinally mediated effect: central delay, 491, 493; diffuse pattern of input, 492, 494; low threshold, 491, 493 facilitation (early), 493; of the: H reflex, 492, 493; on-going EMG, 492, 493; PSTHs, 491-2, 493, 497 rostral location of the interneurones, 493-4 lumbar propriospinal pathways, organisation, 494-500 afferent excitatory input, 494-6 convergence of: afferents from different muscles, 47, 495, 496 convergence of: group I, 305-6, 494; including Ia, 494; group II, 494 diffuse distribution, 494 disclosure of connections with corticospinal facilitation, 498 peroneal-induced excitation of quadriceps, 258-60, 494-5, 496 strength, 494-5 corticospinal control, 498-500 convergence of corticospinal and peripheral inputs, 498-500; which interneurones?, 498-500

wore information

Index	619
-------	-----

effect on feedback inhibitory interneurones, 500; dominant effect, 500 feedback inhibition, 496-7 heteronymous inhibition, 496-7 homonymous inhibition, 496: disclosed by cortical stimulation, 496; weakness, 496 lack of cutaneous inhibition, 496 inhibitory projections on motoneurones, 497-8 from plantar muscles to extensors, 497 medium-latency reciprocal inhibition, 497-8 which interneurones?, 498 lumbar propriospinal pathways, physiological implications, 500-3 unstable stance, 502 voluntary contraction of antagonist muscles, 217, 219, 503, 519-20 voluntary contraction of the target muscle, 14, 26, 27, 47, 500 - 2dominant suppression, 500-2; disfacilitation, 502 weak facilitation, 500-2 walking, 503: quadriceps excitation, 318, 502, 547; soleus inhibition, 547 lumbar propriospinal pathways, possible function, 502-3 focus of the descending motor command to active motoneurones, 502-3 relaxation of antagonist muscles during voluntary contraction, 217, 219, 503, 519-20 walking prevention of excessive Ia activity in soleus, 503, 547 stabilisation of the knee, 319, 547 lumbar propriospinal pathways, studies in patients, 503 Parkinson's disease, 277, 503, 588 spasticity, 277, 503, 566-7 how it could produce spasticity, 566 importance of contribution, 567 methodology, 567 monoaminergic depression of group I excitation, 324 spinal spasticity, 322, 503, 504, 581 quadriceps: effect of: clonidine, 322: DOPA, 322; increased group I excitation, 503; group I-group II excitation, 503; positive feedback via excitation of γ motoneurones, 567-8, 581; underlying mechanisms, 324, 581 soleus, 503 stroke, 322, 503, 504, 577 affected side, 322, 503 effect of tizanidine, 322 unaffected side, 322, 503 underlying mechanisms, 322-4, 503, 577

M1 response to stretch, see stretch reflex M2 response to stretch, normal subjects hand muscles, 90-2, 583 lower limb muscles in stance bilateral response, 313 effects of the postural set, 313, 541 evoked by perturbations of stance, 293, 539 functional role, 314, 541 group II in origin, 297-9 responses in the kinematic chain, 542; ankle and hip strategies, 542 overlap with group Ia excitation, 3, 301 proximal arm muscles, 92 walking, 316-18 depending on the perturbation, 548: translation, 316; vertical, 316-18 function, 318, 549 heteronymous muscles, 316 tibialis anterior, 316, 318, 548 triceps surae, 316-18, 548 wrist muscles, 583 M2 response to stretch, studies in patients Parkinson's disease increased response, 583: hand muscles, 583, 584; wrist muscles, 583, 584 later part, 584; underlying mechanisms, 584 lower limb muscles in stance, 326, 584, 589-90; influence of the postural set, 326, 589-90 peripheral neuropathies, 320 stroke, 322 maturation cutaneomuscular responses, 423 heteronymous Ia excitation, 86 plantar response, 404 medium-latency response to stretch, see M2 response MEP (motor evoked potential), see cortical stimulation methodology, comparison of results from different methods changes in excitability of corticospinal neurones electrical vs. magnetic stimulation of the motor cortex, 44, 424, 430 - 2contamination of the H reflex by Ib inhibition: modulation of the H reflex vs. on-going EMG, 14-15, 16, 301-2, 310-12 non-monosynaptic transmission of the cortical command modulation of the H reflex vs. on-going EMG and MEP, 44, 307-8, 309, 310, 471-3, 500 presynaptic inhibition of Ia terminals modulation of the H reflex vs. corticospinal excitation: MEP, 44, 168, 343-4; PSTH, 342

modulation of H reflex vs. on-going EMG, 27, 340, 365, 545

620 Index

methodology, comparison of results (cont.) monosynaptic excitation vs. D1 inhibition of the H reflex, 347 methodology used to assess motoneurone excitability coherence analysis, 48-9 cortical stimulation, 39-41, 45 F wave, 21-2, 24 H reflex and tendon jerk, 1-21 on-going EMG, 24-6, 28 PSTHs of single units, 28-30, 37 unitary H reflex, 37-9 methodology used to study spinal pathways α motoneurone excitability, 561–3 cervical propriospinal pathways, 455-60 cutaneous reflexes, 391-9 fusimotor activation, 117-26 group Ib pathways, 249-56: excitation, 255; inhibition, 249 - 55group II excitation, 293-302 lumbar propriospinal pathways, 491-4 monosynaptic Ia excitation, 66-77; heteronymous, 70-7; homonymous, 66-70 post-activation depression (Ia fibre-motoneurone), 97-9 presynaptic inhibition of Ia terminals, 340-7 reciprocal Ia inhibition, 201-9 recurrent inhibition heteronymous, 161-9; homonymous, 155 - 61microneurography, 119-24 basic methodology, 119-20 bias towards large fibres, 123 identification of axons, 120-2 dynamic sensitivity, 121-2 twitch test, 120-1: Golgi tendon organs, 123; spindle endings, 116, 121, 122, 125 limitations, 126 microelectrode, 119, 120 responses of various endings Golgi tendon organ, 123 primary ending, 116, 121, 125, 128, 132 secondary ending, 120, 121, 122, 132 uncertainties, 116, 123-4 see also muscle spindles, Golgi tendon organs mid-thoracic nucleus, 494 mirror movements (patients with bilateral corticospinal projections), used to investigate cutaneomuscular responses, 423 long-latency stretch responses, 91 monoamines

selective blockade of group II excitation cat, 292 humans, 299 spasticity, 321, 324-5, 568 effects on group II excitation, 322, 568 effects on group I excitation, 322, 568; underlying mechanisms, 324 interpretation with caution, 568 therapeutic action, 568 see also clonidine, DOPA, tizanidine monosynaptic Ia excitation, background from animal experiments, 64-6 heteronymous projections, 63, 65-6 initial findings, 64 monosynaptic projections to motoneurones, 65: heteronymous, 65; homonymous, 64 primary endings and Ia afferents, 64 projections to motoneurones of different type, 65 stretch reflex, 66 monosynaptic Ia excitation, methodology, 66-77 critique of the tests: heteronymous, 70, 72-3 homonymous, 70 evidence for Ja excitation, 67-9, 70, 73-7 cutaneous stimuli, 77, 85 elevation of the threshold by tendon vibration, 76 facilitation by homonymous volley, 69 ischaemia, 68, 69 low electrical threshold, 64, 67-9, 75 tendon taps, 67, 71, 75-6 H reflex, homonymous at rest, 4, 66-7, 68, 79 during contraction, 69, 79, 80, 95 initial part of the excitation, 15, 16, 67 large range of electrical thresholds in humans, 77-8 decrease in latency, 77, 78 underestimation of: monosynaptic latency, 78; strength of Ia projections, 78 mode of homonymous conditioning stimulation, 69 modulation of heteronymous H reflex, 70, 71 ongoing EMG, 71, 73 PSTHs of single units: heteronymous, 33, 70-1, 72, 73, 85; homonymous, 67, 68, 69-70, 79 monosynaptic latency heteronymous, 70-3; bidirectional connections, 73, 74, 77 homonymous: in soleus, 66-7; other muscles, 70 monosynaptic Ia excitation, organisation, 79-86 heteronymous connections, 81-6

More information

between close synergists: lower limb, 81-2; upper limb, 83-4 between 'non-synergist' ankle muscles, 82 pattern in the lower limb, 81-3; comparison with distribution of recurrent inhibition, 170 pattern in the upper limb, 83-6 to antagonists at another joint, 83 transjoint connections: lower limb, 83; upper limb, 84-6 homonymous excitation, 2, 79-81 all motoneurones: H reflex, 79; PSTH, 79 orderly recruitment, 3-4, 79-81; with exceptions, 79, 81; presynaptic inhibition, 347-8 limitation due to contamination by Ib inhibition, 14-15, 67, 70, 81, 301-2, 493.500 presynaptic inhibition, 13, 81 maturation, 86 phylogenetic differences, 63: lower limb, 83, 92; upper limb, 84 reciprocal Ia excitation newborn, 86; adult, 86 monosynaptic Ia excitation, physiological tasks, 87-94 contribution to the short-latency spinal stretch reflex, 87-90, 293, 320 hopping, 87-8 landing: quadriceps, 88-9; soleus, 88; triceps brachii, 89, 521 running: quadriceps, 87; soleus, 87, 88, 367 standing: not involved in quiet stance, 537; perturbations to stance, 89-90, 313, 539, 540-1; unstable stance, 94, 537-8 walking, Ia feedback to extensors: ankle, 89, 545; knee, 545 walking, soleus Ia stretch reflex, 89, 548 monosynaptic Ia excitation, possible function servo-assistance in movement: co-contractions of antagonists, 135, 532; hinge joint movements, 135, 516; tonic contractions, 122, 133, 512 stretch reflex: interaction with motor programs, 87; load compensation, 87 synergies through heteronymous connections, 512 grasping, 94, 528 stance and gait, 93-4, 528, 537-8, 550 walking prevention of excessive Ia activity in soleus, 93, 546 stabilisation of the ankle: Ia projections, 93, 546; Ia spinal stretch reflex, 89, 548 see also servo-assistance, stretch reflex monosynaptic Ia excitation, studies in patients (H reflex), 95-6 Parkinson's disease: H_{max}/M_{max} ratio, 584-5; reflex threshold, 585; recovery cycle, 585 peripheral neuropathies and nerve lesions, 95-6; location, 95 reflex irradiation, 96, 131

spasticity, H reflex, 562; developmental slope, 562; Hmax/Mmax ratio, 562; recovery cycle, 562; reflex threshold, 562; transmission of the afferent volley, 562 spinal spasticity, H_{max}/M_{max} ratio, 580stroke, H_{max}/M_{max} ratio: FCR, 576; soleus, 576 monosynaptic Ia facilitation to assess presynaptic inhibition of Ia terminals critique, 346 evidence for presynaptic inhibition, 347 facilitation of the: H reflex, 345-6; in PSTHs, 346-7 initial bins, 15, 16, 67 monosynaptic reflex apparent simplicity, 1, 11 different afferent volleys of H and tendon reflexes, 2-3, 117 - 18initial studies: cat, 1; humans, 2 orderly recruitment of motoneurones, 3-4 pathway, 2 principles of monosynaptic reflex testing, 3, 4 reliability, 1-2 see also H reflex, tendon jerk motoneurone, see α motoneurones, γ motoneurones motor learning, 530-1 efference copy, 531 γ drive, 137, 138, 530 projections to ascending tracts, 530-1 motor tasks, changes in spinal pathways changes in cervical propriospinal excitation, 474-6 cutaneomuscular spinal responses, 427, 429-30 fusimotor drive, 131-8 group II excitation, 310-20 lumbar propriospinal excitation, 500-3 non-reciprocal group I inhibition (wrist), 524-6 Ib inhibition, 267-75 presynaptic inhibition of Ia terminals, 355-67 reciprocal Ia inhibition, 217-29 recurrent inhibition, 173-84 synaptic efficacy: group II excitation, 310; monosynaptic Ia excitation, 97; non-reciprocal group I inhibition, 212-14; reciprocal Ia inhibition, 221 withdrawal reflexes, 412-14 co-contraction of antagonists, 531-5 co-ordinated synergies, 527-31 gait. 542-50 isometric tonic contraction, 512-15 movements at ball joints, 522-6 movements at hinge joints, 515-22 postural tasks, 535-42

622 Index

motor threshold (1 \times MT), 6, 7 multiple corticospinal volleys, 40-1 D wave, 40, 43 I waves, 40-1, 43, 44 summation with peripheral volleys, 309, 498 multiple sclerosis, changes in spinal pathways Ib excitation of antagonists, 277 post-activation depression, 99, 100 presynaptic inhibition of Ia terminals, 369 reciprocal Ia inhibition: at rest, 230, 231, 581; during voluntary contraction, 231-2; plasticity, 233 muscle fibre properties, changes in parkinsonian rigidity, 582-3 spasticity, 572-3 muscle spindles afferent innervation, see group Ia and group II afferents differences in cats and humans, 115-16 differences in different muscles, 115 efferent innervation, see γ and β efferents 'in-parallel' response, 113 sensory endings, see primary and secondary endings spindle density, 117 structure, 114, 115 mutual inhibition of interneurones non-reciprocal group I interneurones (wrist), 214, 524, 525 Ib interneurones cat. 246 cutaneous control, 254, 261-2 reversal from facilitation to suppression of Ib inhibition when increasing the input, 256: group I, 258; corticospinal, 265, 269, 270; vestibulospinal, 265 opposite Ia interneurones cat, 199 patients with spasticity, 232 voluntary contraction, 222, 223, 225, 520 walking, 229 Renshaw cells, 154, 176 myotatic reflex, see stretch reflex myotatic unit, 65 natural reciprocal inhibition, 217-19 origin: descending, 217-19; group I, 217 time course, 217, 218; prior to EMG activity, 217 underlying mechanisms, 217-19: post-activation depression, 217; presynaptic inhibition, 217; propriospinally

mediated inhibition, 217–19, 519–20; reciprocal Ia inhibition, 217, 519

nerve blocks, *see* anaesthetics, ischaemic, pressure blocks nociceptive afferents

control of Ib inhibition, 265: cutaneous afferents, 265; muscle afferents, 265 see also: Ao afferents, FRA pathways, RIII reflex, withdrawal reflexes non-monosynaptic group I excitation, see cervical and lumbar propriospinal neurones non-reciprocal group I inhibition, 245, see group Ib inhibition non-reciprocal group I inhibition at wrist level, organisation, 522-4 absence of evidence for pure Ia origin, 211 absence of post-activation depression, 212-14 absence of recurrent inhibition, 171-3, 207, 208 convergence of group I afferents from several different muscles, 212, 258, 524 corticospinal excitation, 524 disynaptic connection, 205, 206 mutual inhibition of interneurones, 214, 524, 525 not between purely antagonistic muscles: clenching, 211-12, 525; wrist abduction, 211, 522 organisation in subsets, 524 potency, 524 non-reciprocal group I inhibition at wrist level, physiological tasks, 524-6 voluntary co-contraction of antagonists, 532 voluntary contraction changes in pathways to: active motoneurones, 524; antagonistic motoneurones, 524-5 mechanisms involved: corticospinal, 524, 525; group I discharge, 525-6 possible function, 525-6 non-reciprocal group I inhibition at wrist level, studies in patients, 234 dystonia, 234, 372 hyperekplexia, 214 Parkinson's disease, 234, 587; voluntary contraction, 591 stroke, 234, 577; correlation with spasticity, 577 noradrenaline, see noradrenergic agonists noradrenergic agonists used to depress group II cat, 292 normal humans, tizanidine, 299, 318 spastic patients, 321, 324-5, 568: clonidine, 322; DOPA, 322; tizanidine, 322

occlusion

- cervical propriospinal neurones: not involved in the reversal of corticospinal excitation, 466; during contraction, 476
- group II interneurones: group I and group II excitations, 301, 306

More information

lumbar propriospinal neurones: corticospinal excitation, 500 Ia interneurones: Ia and cutaneous, 214; Ia and corticospinal inputs, 216; tonic contraction of the antagonist, 220 Ib interneurones: multiple afferent inputs, 256; Ib from different muscles, 258; Ib and corticospinal, 265; vestibulospinal, 265; tonic contraction, 270 PAD interneurones: D1; inhibition, 344-5, 364 Renshaw cells, voluntary contraction, 176 oligosynaptic group I excitation, 245, see group Ib excitation on-going EMG modulation, general features advantages, 27-8 afterhyperpolarisation, 28 different sensitivity to inhibition than the H reflex, 25, 26-7, 203 - 4discrepancies with the modulation of the H reflex, 26-7; gating the afferent volley of the H reflex, 14-15, 26, 27, 340 disfacilitation vs. inhibition, 25, 416-18, 473 initial studies, 24 limitations, 28 motoneurones involved, 25 underlying principles, 24-5 on-going EMG modulation, methodology assessment of the central delay, 25-6 basic methodology with rectified EMG, 24-5 cutaneous reflexes, 396, 404, 414-15 unrectified EMG, 25 on-going EMG modulation used to study cervical propriospinal pathways, 457, 458-9, 471-3 cutaneomuscular responses, 414-15 cutaneous pathways, 396 effects of noxious cutaneous stimuli, 404 group II pathways, 297 lumbar propriospinal pathways, 493, 502 monosynaptic Ia excitation (heteronymous), 73 presynaptic inhibition of Ia terminals, 27, 340 reciprocal Ia inhibition, 203-4 recurrent inhibition (heteronymous), 161-9 onset of movement, focusing action of, 520-1 cervical propriospinal excitation, 476 fusimotor drive, 135, 521 non-reciprocal group I inhibition (wrist), 525 Ib inhibition, 270, 521 presynaptic inhibition of Ia terminals, 359-60, 520 recurrent inhibition, 517, 520 see also timing of changes in spinal pathways during movement orderly recruitment, see α motoneurones, recruitment order organisation and pattern of connections cervical propriospinal pathways, 460-71

group II pathways, 302-10 lumbar propriospinal pathways, 494-500 monosynaptic Ia excitation, 79-86 non-reciprocal group I inhibition (wrist), 522-4 Ib pathways, 256-67 presynaptic inhibition of Ia terminals, 347-55 reciprocal Ia inhibition, 209-17 recurrent inhibition, 169-73 withdrawal reflexes, 399-14 organisation of spinal circuitry at wrist level, 522-4 differences with hinge joints, 522-4 non-noxious cutaneomuscular responses, 526 non-reciprocal group I inhibition, 211-14, 524 absence of evidence for: pure Ia origin, 211; post-activation depression, 212-14; recurrent inhibition, 171-3.208 convergence of: group I afferents, 212, 524: from elbow, 212; homonymous, 212; Ib afferents, 212 corticospinal excitation, 524 organisation in subsets, 524 mutual inhibition, 214, 524 potency, 524 wrist movements, 524-6 presynaptic inhibition of Ia terminals corticospinal control: facilitation, 353, 524; depression, 353 cutaneous control, 350 wrist movements, 362-3, 526; non-specific decrease, 363, 526, 532; possible increase, 526 recurrent inhibition between FCR and ECR, 171, 522 wrist movements, 534 synergies at wrist level: clenching, 211-12, 525; wrist abduction, 211, 522 organisation of spinal interneurones in subsets with respect to muscle afferent input: cervical propriospinal neurones, 468-9 with respect to target motoneurones interneurones mediating withdrawal reflexes, 407 non-reciprocal group I interneurones (wrist), 524, 525 Ia interneurones, 199 Ib inhibitory interneurones, 257 PAD interneurones, 348, 358, 363 oscillations during movement, prevention of, 512 limitation of the stretch reflex during co-contraction of antagonists: ball joints, 534-5; hinge joints, 534 post-activation depression, 97 presynaptic inhibition, 359

cutaneous reflexes (low-threshold afferents), 414-32

fusimotor system, 127-30

624 Index

PAD (primary afferent depolarisation), 337 PAD interneurones, cat FRA terminals, 390 group II terminals, 292 Ia terminals, 337 Ib terminals, 248 pain parallel with RIII reflex, 399-400 RIII reflex used to monitor medication for pain, 437 paired H reflex technique, see recurrent inhibition (homonymous), methodology, 155-61 Parkinson's disease, findings at rest, transmission in spinal pathways, 584-9 absence of consistency, 589 α motoneurone excitability, 584–6 F waves, 585 H reflex: H_{max}/M_{max} ratio, 584–5; reflex threshold, 585; recovery cycle, 585 inconsistencies, 585-6 **MEP** 585 fusimotor drive, 140-1, 586 indirect evidence, 586 insufficient data, 586 microneurography, 586 group II excitation, 326, 584, 588-9 correlation with rigidity, 326, 589 underlying mechanisms, 588 lumbar propriospinal neurones, 277, 503, 588 non-reciprocal group I inhibition (wrist), 234, 587 Ib inhibition (ankle), 276-7, 588 correlation with rigidity, 276, 588 effect of treatment, 588 underlying mechanisms, 277, 588 post-activation depression, 585 presynaptic inhibition of Ia terminals, 371, 586-7 homonymous vibratory inhibition, 371, 587 lower limb, 371, 586 upper limb, 371, 587 reciprocal Ia inhibition, 233-4, 587 tonic inhibition, 587 underlying mechanisms, 587-8 recurrent inhibition, 187, 589 transcortical inhibition, 437, 589 withdrawal reflexes, 436-7, 589 Parkinson's disease, findings during motor tasks, 589-92 cervical propriospinal excitation, 484-5 compensatory mechanism, 485, 592 increased transmission of the descending command, 485, 591

group II excitation in perturbations to stance, 326, 589-90 backward translation, 590 functional implications, 590 influence of the postural set, 326, 589-90 underlying mechanisms, 326, 590 relaxation of the antagonists, 590-1 functional implications, 591 non-reciprocal group I inhibition (wrist), 591 reciprocal Ia inhibition, 234, 590-1 underlying mechanisms, 591 parkinsonian akinesia post-activation depression, 585 presynaptic inhibition of Ia terminals, 371, 586 parkinsonian rigidity, 582-4 changes in muscle fibre properties, 582-3 conflicting results, 582-3 elbow muscles, 582 gait, 582 general features clinical characteristics, 582 depending on afferent inflow, 582 inability to relax, 582, 583 involvement of spinal pathways γ drive, 140–1 group II excitation, 326, 583-4, 589 Ib inhibition, 276, 588 presynaptic inhibition of Ia terminals, 371, 586 reciprocal Ia inhibition, 587 transcortical Ia pathways, 584 long-latency stretch reflex (M2), 583-4 correlation with rigidity, 584 increase, 583 later part, 583, 584; underlying mechanisms, 584 origin, 583-4: distal muscles, 583; wrist muscles, 583, 584 short-latency stretch reflex (M1), 583 parkinsonian tremor, 141 pattern of connections, see organisation and pattern of connections perception of force, 246-7 period prior to voluntary EMG, see timing of changes in spinal pathways during movement peripheral neuropathies and nerve lesions F wave, 24 group II-mediated excitation, 320 H reflex, 95-6 location of the lesion cutaneomuscular spinal responses, 437 H reflex, 95 spinally mediated Ia stretch reflex, 320

Index 625

perturbations to stance, 538-42 ankle and hip strategies, 542 stretch responses in ankle muscles, 539-41 conflicting results, 539 cutaneous contribution, 540 long-latency in the antagonist, 540: function, 541; origin, 540; possibly transcortical, 540 long-latency in the stretched muscle, 539-40; functional stretch reflex, 539 medium-latency, 293: distribution, 293, 539; function, 314, 541; group II origin, 91, 297-9; influence of the postural set, 313, 541; underlying mechanisms, 314 short-latency, 293: distribution, 539; function, 320, 540-1; Ia origin, 89-90, 320 stretch responses in the kinematic chain, 541-2 group II excitation, 313, 542 responses in foot muscles, 312-13, 541-2 studies in patients Parkinson's disease, 326, 589-90 peripheral neuropathies, 320 stroke, 322 pharmacology group II excitation, 292, 299, 321, 324-5, 568 presynaptic inhibition of Ia terminals, 337 reciprocal Ia inhibition, 198-9 recurrent inhibition of: motoneurones, 151, 152, 159-60; Ia interneurones, 208 phylogenetic differences cervical propriospinal system, 455, 479 heteronymous group II excitation, 305 heteronymous Ia excitation, 63: lower limb, 83, 92; upper limb.84 heteronymous recurrent inhibition: lower limb, 169-70; upper limb, 170-1 inhibition from group II afferents, 307 physiotherapy action on spasticity, 556 effects on reciprocal Ia inhibition, 233 plasticity, 572 placing reaction, 427 cat, 385-7 humans: biceps femoris, 427; peroneus longus, 427 plantar responses, 402-4 Babinski response, 433-4 dysfunction of the upper motor neurone, 434 extensor hallucis longus, 402, 403, 434 pathophysiology, 434 maturation, 404

methodology, 392, 402, 434 electrical stimulation, 402, 434 extensor hallucis longus, 402, 434 mechanical stimulation, 392, 402, 434 normal functional organisation, 402-4 protective function, 404 plasticity basis for physiotherapy, 572 changes after spinal cord lesions in animals, 572: sprouting, 572; supersensitivity, 572 changes in muscle fibre properties in: Parkinson's disease, 582-3; spasticity, 572-3 late withdrawal responses in normal subjects, 410; influence of: continuous stimulation, 410; hypnosis, 410; posture, 410 possible cause of α motoneurone hyperexcitability, 561, 572 post-activation depression in: Parkinson's disease, 585; spasticity, 99-100, 572 reciprocal Ia inhibition, 232-3 normal subjects, 210, 232 spasticity: frequent peroneal stimulation, 233, 572; training, 233 plateau potentials normal subjects, 20 spasticity, 563, 580 post-activation depression at the Ia fibre-motoneurone synapse, 96-100 background from animal experiments, 96; effect on motoneurones of different size, 96 cause of misinterpretations when using the H reflex circumstances other than changes in the stimulus rate, 13, vibration of the homonymous tendon, 341, 368, 371, 565 methodology, 97-9 increasing the stimulus rate for the H reflex, 97-9: at rest, 13-14, 97-8, 99; during contraction, 98, 99 stretch of the tested muscle, 97, 98 motor tasks effect on motoneurones of different type, 99 functional implications, 97, 512, 516 studies in patients Parkinson's disease, 585 spasticity, 96, 99-100, 566; plasticity, 99-100, 572 spinal cord lesions, 99, 100, 580; multiple sclerosis, 99; trauma, 99 stroke: affected side, 99, 100, 577; unaffected side, 99, 100, 579

More information

626 Index

post-activation depression in other spinal pathways
background from animal experiments, 248
functional significance, 97
group II excitation, 310, 512–14
non-reciprocal group I inhibition (wrist), 212–14
reciprocal Ia inhibition
α - γ co-activation during tonic contraction, 14, 221;
functional implications, 222, 519
stretch of the antagonistic (tested) muscle, 217
recurrent pathway, 176
withdrawal reflexes, 411
postural tasks, 535–42; see: perturbations to stance, quiet
stance, unstable stance
pressure block of γ efferents, 117, 119, 133
presynaptic inhibition of cortico-motoneuronal projections,
342–3
presynaptic inhibition of group I terminals to cervical
propriospinal neurones, 475, 476
presynaptic inhibition of group II terminals, 292
presynaptic inhibition of non-nociceptive cutaneous afferents,
388
presynaptic inhibition of nociceptive cutaneous afferents
cat, 390
tactile depression of withdrawal reflexes, 412
presynaptic inhibition of Ia terminals, background from animal
experiments, 337–40
descending input, 338, 339
excitatory, 339: corticospinal, 339; tonic level of presynaptic
inhibition, 338, 339; vestibulospinal, 339
inhibitory, 339: corticospinal, 339; reticulospinal, 339
general features, 337–9: electrophysiology, 338–9; location,
337; mechanisms, 337; organisation, 338
initial findings, 337
PAD interneurones, 337
peripheral input, 338, 339: excitatory, 339; inhibitory, 339
presynaptic inhibition of Ia terminals to Ia interneurones,
200, 340
selectivity of the control of PAD interneurones, 339–40
presynaptic inhibition of Ia terminals, methodology, 340–7 activation of PAD interneurones by a heteronymous group I
vollev. 341–5
comparison of H reflex and corticospinal excitation: MEP,
343–4; PSTH, 342
critique, 344–5, 364, 365–6: drawbacks inherent to H reflex
technique, 344; occlusion, 344–5, 364; presynaptic
inhibition of the conditioning volley, 364; spread of the
stimulus, 344; superimposed post-synaptic facilitation,
344, 364
D1 inhibition, 343-4: lower limb, 344; upper limb, 343-4

inhibition of the H reflex by a brief vibration or tap, 341-2 underlying principle, 340-1 changes with ageing, 368 discrepancy between H reflex and on-going EMG, 340 critique, 340 gait, 365, 545 underlying principle, 27, 340 evidence for presynaptic inhibition, 347 comparison of results with heteronymous facilitation and D1 inhibition, 347 experiments during voluntary contraction, 347 investigations of single units, 347 homonymous vibratory inhibition of the H reflex, 341 critique, 341, 368, 371, 565 vibration paradox, 341 monosynaptic Ia facilitation of the H reflex, 345-6 critique, 346 large facilitation required, 346 underlying principle, 345 validation, 346 techniques using single units, 346-7 PSTHs, 346-7; initial bins, 16, 67, 346, 349, 352, 362, 364 unitary H reflex, 347 presynaptic inhibition of Ia terminals, organisation, 347-55 corticospinal projections, 350-3 lower limb: dominant depression, 350-1, 352, 353; convergence with cutaneous input, 353; focused drive, 351; possible facilitation, 353 upper limb: dominant facilitation, 352, 353, 524; functional implications, 353; possibly tonic, 370; reversed by cutaneous stimuli, 353 cutaneous inhibition, 350 lower limb, 350, 420; local sign, 350 upper limb, 350; absence of local sign, 350; tonic effect, 350 group I excitation, 348-50 Ia afferents, 350; pattern, 350 Ib afferents, 350 organisation in subsets, 348 convergence, 348 divergence, 348 with respect to target motoneurones, 348, 356, 357, 358, 363 produced by late FRAs, 408 projections on motoneurones of different type, 347-8, 349 sensitivity of the stretch reflex to presynaptic inhibition, 354-5 functional implications, 355 underlying mechanisms, 354-5 tonic level, 338, 353-4 vestibulospinal facilitation, 353

More information

presynaptic inhibition of Ia terminals, physiological implications, 355-67 co-contraction of antagonists ankle, 361, 362, 532; underlying mechanisms, 361, 362 wrist, 532 contraction of antagonists, 360-1 timing: before, 360; onset, 360; ramp, 360-1 tonic contraction, 361 underlying mechanisms, 360-1 contractions of remote muscles, 133, 361-2 contraction of synergists, 359-60 presynaptic inhibition to inactive motoneurones, 357, 359 underlying mechanisms, 357, 359 contraction of the target muscle, 355-6, 357, 358 force-related, 356, 358 timing: before, 358; onset, 355, 356; ramp, 356, 358; ramp end. 358 tonic contraction, 358 underlying mechanisms, 356, 357, 358-9 contractions of wrist muscles, 362-3, 526 co-contractions of antagonists, 532 non-specific decrease, 363, 526, 532 possible increase, 526 underlying mechanisms, 363 quiet stance, 363-5: quadriceps, 363, 364; soleus, 363-4; tibialis anterior, 363 running, 367 walking, 365-7 Ia feedback to motoneurones: quadriceps, 365, 545; soleus, 365-6.545 Ia feedback to Ia interneurones, 229 presynaptic inhibition of Ia terminals, possible function active motoneurones involved in a selective contraction Ia feedback increased, 359; control of: force and speed, 359, 517-18; timing beginning, 359; later, 359 Ia feedback to inactive synergists decreased: selectivity of movement, 94, 359-60, 517, 529 reciprocal Ia inhibition depressed, 225, 361, 520 antagonistic motoneurones reciprocal Ia inhibition facilitated, 222, 519; stretch reflex, 361 co-contractions: reciprocal Ia inhibition depressed, 226-7, 361, 532; stretch reflex, 361 quiet stance, 364-5 quadriceps, 364 soleus, 364-5: reciprocal Ia inhibition, 364-5; stretch reflex, 364 running, 367

walking prevention of excessive Ia activity in soleus, 366-7, 546 stabilisation of: ankle, 229, 546; knee, 365, 547 yield of the knee, 365, 547 presynaptic inhibition of Ia terminals, studies in patients, 367-72 dystonia, 371-2 D1 inhibition, 371-2: early phase, 371-2; late phase, 372 group III-induced presynaptic inhibition, 372 underlying mechanisms, 372 methodology, 367-8 D1 inhibition, 367, 565-6 heteronymous facilitation, 566 heteronymous tendon tap, 368, 566 Parkinson's disease, 371, 586-7 correlations with: akinesia, 371; rigidity, 371 homonymous vibratory inhibition, 371, 587 lower limb, 371, 586 upper limb, 371, 587 spasticity, 368-70, 565-6 animal models, 565 how it could produce spasticity, 565 importance of contribution, 370, 566 overestimation, 368, 566: homonymous vibration, 368, 565; sensitivity of the stretch reflex to presynaptic inhibition, 368 variations with the level of the lesion, 566 voluntary contraction, 370, 574, 575 walking, 368, 370-1, 575 spinal spasticity, 369, 580; underlying mechanisms, 370, 580 stroke, 368-9, 576 lower limb, 368-9, 576 upper limb, 369, 576 underlying mechanisms, 369-70, 576 presynaptic inhibition of Ib terminals cat, 248 spasticity, 278, 577 voluntary contraction, 270, 272 presynaptic inhibition of reciprocal Ia inhibition background from animal experiments, 200-1 Ia terminals on interneurones, 200 terminals of the interneurones, 201 reciprocal Ia inhibition depressed during co-contractions of antagonists, 226-7, 361.532 depressed to active motoneurones, 225, 361, 520 facilitated to antagonist motoneurones, 222, 519

nore information

628 Index

primary endings (muscle spindle) cat, definition, structure, 114, 115 dynamic sensitivity to perturbations of: stance, 89 walking, 316 dynamic sensitivity used in identification, 120-1 origin of Ia afferents, 64, 114 recordings from, 116, 121, 125, 128, 132 sensitivity to stretch and vibration in the cat, 64, 114 sensitivity to vibration in humans, 130, 132 propriospinal neurones, 452, see cervical and lumbar propriospinal neurones, group II interneurones propriospinally mediated inhibition of motoneurones from plantar muscles to extensor motoneurones, 497; walking, 503, 547 reciprocal inhibition of soleus (tibialis anterior voluntary contraction) normal subjects, 217-19, 497-8, 519-20 spastic patients, 575 PSTHs (post-stimulus time histograms), general features advantages, 37 initial studies, 29 limitations, 36-7 underlying models, 29 underlying principles, 29, 30 PSTHs, methodology afterhyperpolarisation, 31, 32, 37 assessment of conduction velocity of Ia afferents, 36 basic methodology, 29-32 central delay, 34 cumulative sum (CUSUM), 33-4 initial bins, 15, 16 latency measurements, 32-3 mono- and non-monosynaptic components, 34 multiple peaks, 37 normalisation, 35-6 recording, from a single motor unit, 30-1: characterisation, 31; one motor unit, 30-1; pairs of units, 31; same unit, 31; stable frequency, 31 size and threshold of a change, with stimulation triggered by the previous firing, 33, 34-5, 460 randomly, 34 stimulation: delivered randomly, 31; triggered by the unit firing, 32 stimulus intensity, 32 window, 32 PSTHs, used to investigate projections on motoneurones of different type of cervical propriospinal neurones, 471

corticospinal excitation through propriospinal neurones, 469-71 low-threshold cutaneous afferents, 425 monosynaptic Ia excitation, 79-81 presynaptic inhibition of Ia terminals, 347-8 PSTHs, used to study cervical propriospinal pathways, 457 conduction velocity of Ia afferents, 36 corticospinal projections on cervical propriospinal neurones, 461-3 feedback inhibitory interneurones to cervical propriospinal neurones, 464-7 feedback inhibitory interneurones to lumbar propriospinal neurones, 310, 500 group II interneurones, 46-7, 308-9 lumbar propriospinal neurones, 498 PAD interneurones, 351-3 cutaneous (non-noxious) pathways, 396, 416, 417, 420 group II pathways, 295-7 lumbar propriospinal pathways, 491-3 monosynaptic Ia excitation: heteronymous, 70-3 homonymous, 67, 69-70 non-reciprocal group I inhibition (wrist), 212 Ib inhibition, 249-52, 253-5 oligosynaptic limitation of the H reflex, 14-15, 37 'pool problems', 20, 21, 37 presynaptic inhibition of Ia terminals, 342, 346-7 co-contractions, 361, 362 quiet stance, 363, 364 reciprocal Ia inhibition, 204 recurrent inhibition (heteronymous), 161-8 responses to cortical stimulation, 40 quantitative assessments, difficulties convergence of multiple inputs on interneurones, 261, 301, 306.474 spatial/temporal summation in motoneurones, 301, 316, 474, 512 quiet stance, 535-7 anticipatory control of body sway, 537 changes in transmission in spinal pathways presynaptic inhibition of Ia terminals: quadriceps, 363, 364; soleus, 363, 364-5 recurrent inhibition, 181 spinally mediated Ia excitation, 537 withdrawal reflexes, 414 intrinsic stiffness of the ankle, 536-7 inverted pendulum, 535 multi-sensory feedback, 535-6; absence of redundancy, 536

wore information

ramp contractions co-contraction of antagonists: recurrent inhibition, 180 contraction of the antagonistic muscle fusimotor drive, 135 presynaptic inhibition of Ia terminals, 360-1 reciprocal Ia inhibition, 221 recurrent inhibition, 180 contraction of the target muscle fusimotor drive, 135 presynaptic inhibition of Ia terminals, 358 recurrent inhibition, 174 reaching, role of the cervical propriospinal system cat, 454 possible role in humans, 529-30 reciprocal Ia excitation cerebral palsy, 233, 579 maturation, 86 spread of the mechanical stimulus, 86 reciprocal Ia inhibition, background from animal experiments, 197-201 α - γ linkage in reciprocal Ia inhibition, 198, 201 'direct' inhibition, 197 general features, 198-9: electrophysiology, 199; identification, 198; mode of action, 199; morphology, 198; pharmacology, 198-9 initial findings, 197-8 input to Ia interneurones from, 199-200: descending tracts, 200; cortico-, 200; rubro-, 200; vestibulo-spinal, 200; FRA, 199 mutual inhibition of opposite Ia interneurones, 198, 199 'Ia interneurones', 197 presynaptic inhibition, 200-1: Ia terminals, 198, 200; terminals of the interneurones, 201 projections of Ia interneurones to, 199: α motoneurones, 199; opposite Ia interneurones, 199 recurrent inhibition of Ia interneurones, 152, 154, 198, 200 reciprocal Ia inhibition, methodology, 201-9 critique of tests, 208-9 central delay, 208 encroachment on afferents in other nerves: superficial peroneal, 209; upper limb, 209 propriospinally-mediated inhibition, 209 stimulation of other fibres, 208-9 differences from Ib inhibition, 255 evidence for disynaptic inhibition bidirectional connections: H reflex, 205, 206; PSTH, 203, 205 poor time resolution of the H reflex, 205 evidence for inhibition from Renshaw cells, 205-8 absence at wrist, 171-3, 207, 208

ankle, 171, 206, 207 elbow, 171, 172, 208 pharmacological validation, 207, 208 evidence for Ia origin, 204–5 absence of cutaneous effect, 204 elevation of the threshold by tendon vibration, 203, 205 low electrical threshold, 204 tendon tap, 202, 204 inhibition of H reflex, 201, 202; tendon jerk, 201, 203 on-going EMG, 25, 26-7, 203-4, 223 PSTHs of single units, 204 reciprocal Ia inhibition, organisation, 209–17 corticospinal control, 216 cutaneous control, 214-15 organisation and strength ankle, 202, 209-10: soleus, 202, 210; individual variations, 202, 210; tibialis anterior, 202, 210 elbow, 203, 210, 521 knee, 210-11 recurrent inhibition of Ia interneurones, 171-3, 205-8 vestibulospinal facilitation, 216-17 wrist absence of true reciprocal Ia inhibition, 211-14 see non-reciprocal group I inhibition at wrist level reciprocal Ia inhibition, physiological implications, 217-29 co-contraction of antagonists, 225-6, 227 modulation of: H reflex, 225, 531; PSTHs, 225 onset 225 underlying mechanisms, 225-7: decoupling of motoneurones and Ia interneurones, 225–6, 533; γ drive, 135, 532; presynaptic inhibition, 226-7, 361, 532; recurrent inhibition, 181, 227, 531-2 contraction of antagonistic muscles, 217-23 α - γ linkage in reciprocal Ia inhibition, 198, 219, 223 mechanisms obscuring reciprocal Ia inhibition: occlusion, 220; post-activation depression, 221; presynaptic inhibition, 220 'natural' reciprocal inhibition, 217-18, 219 ramp contractions, 218, 221; prior to EMG activity, 221 tonic contractions, 218, 219-20; blockade of the afferent feedback, 218, 220; conflicting results, 219; individual variations, 219-20; methodological considerations, 219 underlying mechanisms, 221–3, 519: α - γ coactivation, 221-3; descending drive, 221; presynaptic inhibition, 222, 519; recurrent inhibition, 222 contraction of remote muscles, 133, 227 contraction of the target muscle, 223-4, 225 force-related, 223

630 Index

reciprocal Ia inhibition, physiological implications (cont.)
modulation of: H reflex, 223; ongoing EMG, 223
underlying mechanisms, 223–5: mutual inhibition of Ia
interneurones, 223-4; presynaptic inhibition, 225, 361,
520; recurrent inhibition, 225
plasticity in normal subjects, 202, 210, 232
postural activity, 227
walking, 227–9, 546
modulation of: H reflex, 228, 229; ongoing EMG, 228, 229
underlying mechanisms, 229; mutual inhibition of Ia
interneurones, 229; presynaptic inhibition, 229
reciprocal Ia inhibition, possible function
co-contraction, decoupling of motoneurones and
corresponding Ia interneurones, 227; unstable stance, 227
depression of reciprocal Ia inhibition of: active
motoneurones, 225, 517; corresponding Ia
interneurones, 225, 520; control of force, 224, 518
inhibition of antagonistic: motoneurones, 223, 519;
corresponding Ia interneurones, 222, 223, 520
linkage of descending command to motoneurones and
corresponding Ia interneurones, 223, 227, 519
walking, stabilisation of the ankle, 229, 546; cutaneous
facilitation, 214–15, 549
reciprocal Ia inhibition, studies in patients, 229–34
cerebral palsy, 233, 579
hyperekplexia, 233: lower limb, 233; upper limb, 214, 233
Parkinson's disease, 233–4
findings at rest, 233–4, 587: tonic inhibition, 587;
underlying mechanisms, 587–8
voluntary movement, 234, 590–1; underlying mechanisms,
591
spasticity findings at rest, 229–30, 570
distribution extensors-flexors, 232, 570
how it could produce spasticity, 570
importance of contribution, 570
methodology, 229, 570
underlying mechanisms, 232, 570
spasticity, findings during motor tasks
cause of motor impairment, 231-2, 574-5
underlying mechanisms α - γ linkage, 574; corticospinal
drive to Ia interneurones, 574; opposite Ia interneurones,
575; presynaptic inhibition, 574; recurrent inhibition, 575
spasticity, plasticity: frequent peroneal stimulation, 233
training, 233
spinal spasticity
correlation with recovery, 232
multiple sclerosis, 230, 231, 581
spinal cord injury, 230; distribution, 581

stroke, 230, 577; correlation with recovery, 232, 577; underlying mechanisms, 577 reciprocal organisation absent for spinal cutaneomuscular responses: lower limb, 429; upper limb, 427 Ia pathways: cat, 197; hinge joints, 211 Ib pathways: cat, 245; Ib excitation elbow, 258 withdrawal reflexes, 402, 404, 405 recovery from propriospinal lesion, 481 stroke propriospinal transmission, 484 reciprocal Ia inhibition, 233, 577 recruitment gain of the H reflex comparison of results with heteronymous facilitation and D1 inhibition, 347 effect of cutaneous stimuli, 20, 425 limitation of the H reflex method, 18-20 single unit investigations required, 20, 347 recruitment order, see α motoneurones, recruitment order recurrent collaterals from motor axons, 152 recurrent inhibition, background from animal experiments, 151 - 4functional hypotheses, 154 general features, 151-2: electrophysiology, 152; input-output relationship, 152; morphology, 151; organisation, 151; pharmacology, 151, 152; strength, 152 initial findings, 151 input to Renshaw cells from, 152, 152–3: α motoneurones, 152-3; descending tracts, 153; segmental afferents excitatory, 153; inhibitory, 153 projections from Renshaw cells to, 153-4: α motoneurones, 153; γ motoneurones, 153; Ia interneurones, 152, 154, 200; other Renshaw cells, 152, 154; VSCT, 154 recurrent inhibition, methodology (heteronymous), 161-9 critique of the tests, 168-9 evidence for recurrent inhibition, 166-7 antidromic motor discharge, 168; orthodromic motor discharge, 167-8 central delay, 166 duration, 166 threshold related to conditioning motor discharge, 162, 166 inhibition evoked by motor discharge antidromic, 162-4, 166 orthodromic, 162: H reflex, 35, 162, 164, 165; tendon jerk, 162.163 inhibition of, 161-2 MEPs, 165 monosynaptic reflexes, 165

more information

on-going EMG, 165 PSTHs of single units, 163, 164, 165 rest vs. contraction, 169 routine explorations, 169 recurrent inhibition, methodology (homonymous), 155-61 afterhyperpolarisation and recurrent inhibition, 156, 157-9, 161 comparison of H' with a reference H reflex, 160 conditioning and test reflexes, 155-6, 157 contamination by Ib inhibition, 155, 160-1 critique of the method, 160-1 evidence for recurrent inhibition, 157, 159 inhibition related to conditioning reflex size, 157, 158 time course, 158, 159 lesser sensitivity of H' than of the reference H to PSPs, 161 limitations, 160-1 underlying principles, 155 use of antidromic motor volleys is invalid, 154-5 validation animal experiments, 159 pharmacological, 158, 159-60 recurrent inhibition, organisation, 169-73 absence of recurrent collaterals to motoneurones of distal muscles: heteronymous, 170, 171; homonymous, 169 comparison with distribution of Ia excitation, 170 corticospinal control of recurrent inhibition, 173: heteronymous, 172, 173; homonymous, 172, 173; via reticular formation, 173 functional implications of heteronymous distribution: lower limb, 170, 183-4, 529, 538; upper limb, 171 inhibition of motoneurones, 169-71 heteronymous distribution, 169-71: lower limb, 166, 169-70; upper limb, 167, 170-1 homonymous projections to muscles, 169: distal, 169; proximal, 169, 521 inhibition of Ia interneurones, 171-3 absence at wrist, 171-3, 207, 208 ankle, 171, 206, 207 elbow, 171, 172, 208 mutual, between FCR and ECR, 171, 522; function, 534 phylogenetic difference: lower limb, 169-70; upper limb, 170 - 1recurrent inhibition, physiological implications, 173-84 co-contraction of the antagonists ankle, 177, 180, 531-2: ramp, 180; tonic, 180 wrist, 534 contraction of antagonist muscles, 180: ramp, 177, 180; tonic, 180 contraction of the target muscle, 173-9, 514-15, 517

contractions of different types: ballistic, 176; ramp, 174, 175; tonic, 174, 175 heteronymous recurrent inhibition, 178-9 underlying mechanisms: afterhyperpolarisation, 178; descending changes in Renshaw cell excitability, 178; effects of the natural motor discharge, 176 postural tasks: quiet stance, 181, 182; unstable stance, 182, 183 walking, 546 recurrent inhibition, possible function stance: quiet stance, 181; unstable stance, 183-4, 538 voluntary co-contraction of the antagonists: hinge joint, inhibition of motoneurones and Ia interneurones, 181, 532; specific control, 181; wrist, 534 voluntary contraction of the antagonist inhibition of motoneurones, 180, 520 prevention of stretch reflex, 520 voluntary contraction of the target muscle, 179 compensation for muscle fatigue, 174 control of force and speed, 179, 518 control of reciprocal Ia inhibition, 179, 222; mutual inhibition of Ia interneurones, 225 gain hypothesis, 179, 514-15 selectivity: homonymous, 517; heteronymous, 183-4 walking, 547 recurrent inhibition, studies in patients, 184-7 cerebral palsy, 187 hyperekplexia, 187 Parkinson's disease, 187, 589 spasticity, findings at rest, 184, 185 amyotrophic lateral sclerosis, 184, 581 animal models, 569 how it could produce spasticity, 184, 569 importance of contribution, 569 methodology, 184, 569 underlying mechanisms, 186 spasticity, findings during motor tasks, 185, 186–7, 575 spinal spasticity progressive hereditary paraparesis, 185, 186, 581 spinal cord injury, 184, 581 stroke, 184, 185, 577; findings using a flawed technique, 569 redundancy in the function of different pathways contributing to inhibition of antagonists, 520 motor tasks, 511 quiet stance, 536 reference H reflex, see recurrent inhibition (homonymous), methodology

More information

632 Index

reflex reversal cutaneous control of Ib inhibition during voluntary contraction, 259, 262, 265-7 cutaneous reflexes during walking: cat, 387; humans, 430 Ib inhibition during walking: cat, 248; humans, 273-5, 546 propriospinally mediated excitation when increasing the input, 464-7 state-dependent modulation of sensory feedback, 530 reinforcement manoeuvre, see Jendrassik manoeuvre relaxation of antagonists, spinal pathways contributing to, 513, 519-20, 521 normal subjects absence of redundancy, 520 non-reciprocal group I inhibition (wrist), 523, 524-5 Ib inhibition, 273, 520 post-activation depression (stretched muscle), 217 presynaptic inhibition of Ia afferents, 217, 361, 519 propriospinally mediated reciprocal inhibition, 217, 503, 519-20 reciprocal Ia inhibition, 217, 519 recurrent inhibition, 180, 520 see also 'natural reciprocal' inhibition, 217 spastic patients, 573-5 Renshaw cells, 151 Renshaw inhibition, see recurrent inhibition repetition rate cutaneous reflexes, see habituation of cutaneous reflexes, 391 H reflex, 97-9: at rest, 7, 13-14, 97-9; during contraction, 98, 99 reticulospinal control, background from animal experiments cervical propriospinal neurones, 453 group II pathways, 292 lumbar propriospinal neurones, 491 Ib pathways, 248 presynaptic inhibition: group II terminals, 292; Ia terminals, 339 reticulospinal control in spasticity cervical propriospinal neurones, 483-4, 579 presynaptic inhibition of Ia terminals, 370 Renshaw cells, 185, 186 rostral location with respect to motoneurones cervical propriospinal neurone, 459-60 group II interneurones, 303-4 lumbar propriospinal neurones, 493-4 rTMS, 372 RII reflex, biceps femoris, 393, 394, 414 afferent pathway, 418 central pathway, 418-19 habituation, 394

methodology, 394 placing reaction, 427 temporal summation, 394, 418 threshold, 418 RII reflex, other muscles, 396, 417 RIII reflex, biceps femoris, 393, 394 afferent pathway, 399-400: AB, 400; Ab, 393, 400 central pathway, 401 methodology, 394: single shocks, 400; trains, 393, 400 parallel with pain sensation, 393, 399-400 threshold, 400 use to monitor medication pain, 437 running, contribution of spinal pathways heteronymous Ia connections, 93-4, 550 presynaptic inhibition of Ia terminals, 367 short-latency Ia excitation, 87: quadriceps, 87; soleus, 87 secondary endings (muscle spindle) cat, definition and structure, 114, 115, 289 low dynamic sensitivity during perturbations of gait, 316 low dynamic sensitivity used for identification, 121-2 recordings from, 120, 121, 122, 132 sensitivity to stretch and vibration in cats, 114 sensitivity to vibration in humans, 130, 132, 289 selectivity of movement, spinal mechanisms contributing to, 517 cervical propriospinal system focus of descending drive, 476 lateral inhibition, 477, 517 focus of group II excitation, 514 fusimotor drive, 122, 135, 517 lumbar propriospinal neurones (descending inhibition), 502 - 3Ib inhibition, 273, 517 presynaptic inhibition of Ia terminals, 359-60, 517, 529 recurrent inhibition: heteronymous, 183-4, 529, 538; homonymous, 517 sensitivity to facilitation and inhibition H reflexes of different sizes, 16-18 H reflex vs. on-going EMG and PSTH, 25, 26-7, 203-4 paired H reflex technique: H' and reference H reflexes, 161 servo-assistance, 114 group I effects from tibialis anterior to biceps, stabilisation of the knee in walking, 274-5, 547 group Ia projections to α motoneurones perturbations to stance, 89-90, 539, 540-1 unstable stance: heteronymous, 94, 538; homonymous, 538

more information

voluntary contractions: co-contractions of antagonists, 135, 532; hinge joint movements, 135, 516; tonic contractions, 122, 133, 512 walking, stabilisation of the: ankle, 89, 93, 546, 548; knee, 545 group Ia projections to cervical propriospinal neurones, 477, 516 - 17group II projections FRA hypothesis, 389, 513, 514, 529 perturbations to stance, 539, 541; influence of the postural set, 313, 541 unstable stance, heteronymous, 313-14, 538; homonymous, 538 voluntary contractions, 512-14, 529 walking, contribution to soleus activation, 319-20, 545-6 motor learning, 138, 530 mutual reinforcement of Ia and group II excitations, 512 - 14see also co-ordinated activation of various synergies through heteronymous Ia and group II connections spasticity, clinical features and pathophysiology blockade of one mechanism, 560 clinical features, 558 clasp-knife phenomenon, 244, 245, 326, 558 clonus, 139-40, 558 reflex irradiation, 96, 131 synkinetic contractions, 557, 579 variations with the causative lesion, 557-8 contribution to motor impairment, 558-60, 574 absence of relation with stretch reflex exaggeration, 558, 573 - 4conflicting results, 559 overestimation, 560 variations with the underlying cause, 559: cerebral palsy, 559, 574; spinal cord lesion, 559, 574; stroke, 559 definition, 557 longitudinal studies, 556-7 reflex irradiation, 96, 570 heteronymous connections, 570 transmission of vibration, 570 relationship to decerebrate rigidity, 560 common features, 560 differences, 560 mechanisms underlying decerebrate rigidity, 560 stretch reflex exaggeration, 557 increase in tone, 558 reflex gain, 557, 559 reflex threshold, 557, 559 tonic stretch reflex, 557

therapeutic issues, 556 blockade of peripheral nerves by alcohol/phenol, 556 botulinum toxin, 556, 559 oral/intrathecal drugs, 556 physiotherapy, 556 spasticity, findings at rest, transmission in spinal pathways, 560-71 absence of correlation with clinical spasticity, 571 α motoneurone excitability, 560–3 F wave, 562-3 H reflex, 96, 562: developmental slope, 562; $\mathrm{H}_{max}/\mathrm{M}_{max}$ ratio, 562; recovery cycle, 562; reflex threshold, 562; transmission of the afferent volley, 562 how it could produce spasticity, 560 importance of contribution, 563 plateau potentials, 563 fusimotor drive, 139-40, 563-5 animal models, 564 clonus, 139-40 flawed arguments for, 139, 564 how it could produce spasticity, 563 importance of contribution, 564, 565 microneurography, 139, 564 possibility of occurrence, 139, 564-5 group II excitation, 320-6, 567-8 absence of correlations with clinical spasticity, 325 actions of monoamines, 321, 324-5, 568: group I excitation, 568; group II excitation, 568; interpretation with caution, 321-2, 325, 568; therapeutic action, 568 group II pathways and clasp-knife phenomenon, 326 how it could produce spasticity, 567 importance of contribution, 324-6, 568 methodology, 320-1, 567 positive feedback via excitation of γ motoneurones, 325, 567-8 possible mechanisms underlying increased group I excitation, 324: muscle stretch, 324; propriospinal contribution to tendon jerk, 324 non-reciprocal group I inhibition (wrist), 234 Ib excitation to antagonists, 277-9, 569 how it could produce spasticity, 569 importance of contribution, 278-9, 569 methodology, 569 Ib excitation vs. reciprocal Ia inhibition, 230, 277-8; vs. propriospinal excitation, 569 Ib inhibition (ankle), 276, 568-9 how it could produce spasticity, 568 importance of contribution, 569 methodology, 275-6, 568

634 Index

spasticity, findings at rest, transmission (cont.)
Ib inhibition vs. propriospinal excitation, 277, 568
post-activation depression, 96, 99–100, 566
how it could produce spasticity, 566
importance of contribution, 566
methodology, 566
presynaptic inhibition of Ia terminals, 368–70, 565–6
animal models, 565
how it could produce spasticity, 565
importance of contribution, 370, 566
methodology, 367–8: D1 inhibition, 565–6; heteronymous
facilitation, 566; heteronymous tendon tap, 566
overestimation, 368, 566: homonymous vibration, 368, 565;
sensitivity of the stretch reflex to presynaptic inhibition,
368
variations with the level of the lesion, 566
propriospinal excitation, 503, 566–7
how it could produce spasticity: cervical, 567; lumbar, 566
importance of contribution, 567
methodology: cervical, 481, 567; lumbar, 567
reciprocal Ia inhibition, 229–30, 570
distribution extensors-flexors, 232, 570
how it could produce spasticity, 570
importance of contribution, 570
methodology, 229, 570
plasticity: frequent peroneal stimulation, 233; training, 233
recurrent inhibition, 184, 569
animal models, 569
animal models, 569 findings using a flawed technique, 569
,
findings using a flawed technique, 569
findings using a flawed technique, 569 how it could produce spasticity, 184, 569 importance of contribution, 569 methodology, 184, 569
findings using a flawed technique, 569 how it could produce spasticity, 184, 569 importance of contribution, 569 methodology, 184, 569 variations with the level of the lesion, 569
findings using a flawed technique, 569 how it could produce spasticity, 184, 569 importance of contribution, 569 methodology, 184, 569 variations with the level of the lesion, 569 spasticity, findings at rest, underlying mechanisms, 560–72
findings using a flawed technique, 569 how it could produce spasticity, 184, 569 importance of contribution, 569 methodology, 184, 569 variations with the level of the lesion, 569
findings using a flawed technique, 569 how it could produce spasticity, 184, 569 importance of contribution, 569 methodology, 184, 569 variations with the level of the lesion, 569 spasticity, findings at rest, underlying mechanisms, 560–72 abnormal descending control, 571 α motoneurone excitability, 561
findings using a flawed technique, 569 how it could produce spasticity, 184, 569 importance of contribution, 569 methodology, 184, 569 variations with the level of the lesion, 569 spasticity, findings at rest, underlying mechanisms, 560–72 abnormal descending control, 571 α motoneurone excitability, 561 γ drive, 563–4
findings using a flawed technique, 569 how it could produce spasticity, 184, 569 importance of contribution, 569 methodology, 184, 569 variations with the level of the lesion, 569 spasticity, findings at rest, underlying mechanisms, 560–72 abnormal descending control, 571 α motoneurone excitability, 561 γ drive, 563–4 group II excitation, 322–4, 567
findings using a flawed technique, 569 how it could produce spasticity, 184, 569 importance of contribution, 569 methodology, 184, 569 variations with the level of the lesion, 569 spasticity, findings at rest, underlying mechanisms, 560–72 abnormal descending control, 571 α motoneurone excitability, 561 γ drive, 563–4 group II excitation, 322–4, 567 Ib excitation to antagonists, 278, 569
findings using a flawed technique, 569 how it could produce spasticity, 184, 569 importance of contribution, 569 methodology, 184, 569 variations with the level of the lesion, 569 spasticity, findings at rest, underlying mechanisms, 560–72 abnormal descending control, 571 α motoneurone excitability, 561 γ drive, 563–4 group II excitation, 322–4, 567 Ib excitation to antagonists, 278, 569 Ib inhibition, 277
findings using a flawed technique, 569 how it could produce spasticity, 184, 569 importance of contribution, 569 methodology, 184, 569 variations with the level of the lesion, 569 spasticity, findings at rest, underlying mechanisms, 560–72 abnormal descending control, 571 α motoneurone excitability, 561 γ drive, 563–4 group II excitation, 322–4, 567 Ib excitation to antagonists, 278, 569 Ib inhibition, 277 presynaptic inhibition of Ia terminals, 369–70
findings using a flawed technique, 569 how it could produce spasticity, 184, 569 importance of contribution, 569 methodology, 184, 569 variations with the level of the lesion, 569 spasticity, findings at rest, underlying mechanisms, 560–72 abnormal descending control, 571 α motoneurone excitability, 561 γ drive, 563–4 group II excitation, 322–4, 567 Ib excitation to antagonists, 278, 569 Ib inhibition, 277
findings using a flawed technique, 569 how it could produce spasticity, 184, 569 importance of contribution, 569 methodology, 184, 569 variations with the level of the lesion, 569 spasticity, findings at rest, underlying mechanisms, 560–72 abnormal descending control, 571 α motoneurone excitability, 561 γ drive, 563–4 group II excitation, 322–4, 567 Ib excitation to antagonists, 278, 569 Ib inhibition, 277 presynaptic inhibition of Ia terminals, 369–70 propriospinal excitation: cervical, 483–4, 567, 579; lumbar,
findings using a flawed technique, 569 how it could produce spasticity, 184, 569 importance of contribution, 569 methodology, 184, 569 variations with the level of the lesion, 569 spasticity, findings at rest, underlying mechanisms, 560–72 abnormal descending control, 571 α motoneurone excitability, 561 γ drive, 563–4 group II excitation, 322–4, 567 Ib excitation to antagonists, 278, 569 Ib inhibition, 277 presynaptic inhibition of Ia terminals, 369–70 propriospinal excitation: cervical, 483–4, 567, 579; lumbar, 567
findings using a flawed technique, 569 how it could produce spasticity, 184, 569 importance of contribution, 569 methodology, 184, 569 variations with the level of the lesion, 569 spasticity, findings at rest, underlying mechanisms, 560–72 abnormal descending control, 571 α motoneurone excitability, 561 γ drive, 563–4 group II excitation, 322–4, 567 Ib excitation to antagonists, 278, 569 Ib inhibition, 277 presynaptic inhibition of Ia terminals, 369–70 propriospinal excitation: cervical, 483–4, 567, 579; lumbar, 567 reciprocal Ia inhibition, 232
findings using a flawed technique, 569 how it could produce spasticity, 184, 569 importance of contribution, 569 methodology, 184, 569 variations with the level of the lesion, 569 spasticity, findings at rest, underlying mechanisms, 560–72 abnormal descending control, 571 α motoneurone excitability, 561 γ drive, 563–4 group II excitation, 322–4, 567 Ib excitation to antagonists, 278, 569 Ib inhibition, 277 presynaptic inhibition of Ia terminals, 369–70 propriospinal excitation: cervical, 483–4, 567, 579; lumbar, 567 reciprocal Ia inhibition, 232 recurrent inhibition in hereditary paraparesis, 186
findings using a flawed technique, 569 how it could produce spasticity, 184, 569 importance of contribution, 569 methodology, 184, 569 variations with the level of the lesion, 569 spasticity, findings at rest, underlying mechanisms, 560–72 abnormal descending control, 571 α motoneurone excitability, 561 γ drive, 563–4 group II excitation, 322–4, 567 Ib excitation to antagonists, 278, 569 Ib inhibition, 277 presynaptic inhibition of Ia terminals, 369–70 propriospinal excitation: cervical, 483–4, 567, 579; lumbar, 567 reciprocal Ia inhibition, 232 recurrent inhibition in hereditary paraparesis, 186 plastic changes, 571

post-activation depression, 99-100, 572 reciprocal Ia inhibition, 233, 572 spasticity, findings during motor tasks, 573–5 abnormal inhibition of the antagonists, 574, 575; due to Ib facilitation of antagonists, 279, 575 presynaptic inhibition of Ia terminals, 575 propriospinally mediated inhibition of motoneurones, 575 reciprocal Ia inhibition, 231–2, 574–5: α - γ linkage, 574; corticospinal drive to Ia interneurones, 574; opposite Ia interneurones, 575; presynaptic inhibition, 574; recurrent inhibition, 575 recurrent inhibition, 575 presynaptic inhibition of Ia terminals voluntary contraction, 370, 575 walking, 368, 370-1, 575 recurrent inhibition, 185, 186-7, 575 spindle behaviour, 139, 140, 565 synkinetic contractions, 484, 579 spasticity, modification of properties of muscle fibres, 572-3 absence of abnormal stretch reflex, 559, 573 alterations in properties of muscle fibres, 573 changes related to inactivity of motoneurones, 572-3 muscles, 572, 573 contracture, 557, 559, 560, 572 importance in stroke patients, 573 spatial facilitation, background from animal experiments convergence of excitation and inhibition, 45 excitatory convergence in: excitatory interneurones, 45; inhibitory interneurones, 45 underlying principles, 45, 46 spatial facilitation, methodology advantages and limitations, 48 initial sparing, 15, 46, 47, 212, 263, 267, 308-9, 456, 462, 463, 466, 472, 473, 498, 499 limitations of the H reflex method, 47-8 limitations of the PSTH method, 47 methodology for PSTHs of single units, summation in, 46-7: excitatory pathways, 46-7; inhibitory pathways, 14-15 methodology for the H reflex, 46, 47 spatial facilitation, used to demonstrate contamination of the H reflex by Ib inhibition, 14-15 recurrent inhibition of Ia interneurones, 171-3, 205-8 spatial facilitation, used to study convergence on cervical propriospinal neurones, 461-3, 469 feedback inhibitory interneurones to propriospinal neurones: cervical, 464-7, 469, 478; lumbar, 310, 500 group II interneurones, 46-7, 307-9 Ia interneurones, 171-3, 202, 205-8, 214-15, 216-17

wore information

Index	635
-------	-----

Ib inhibitory interneurones, 257-8, 260-7 lumbar propriospinal neurones, 46-7, 307-9, 496, 498 non-reciprocal group I inhibitory interneurones (wrist), 212, 258.524 PAD interneurones acting on Ia terminals, 350-3 Renshaw cells, 173 spatial and/or temporal summation occurring in cervical propriospinal neurones, 460, 461, 469, 474, 476, 477 cutaneous reflex pathways, 391, 392, 394, 396 feedback inhibitory interneurones to cervical propriospinal neurones, 478, 483 group II interneurones, 290, 306, 316 Ia interneurones, 204 Ib interneurones, 261 making difficult quantitative assessment of effects, 261, 316, 474.512 see also convergence, spatial facilitation speed of movement changes in the recruitment order of motoneurones favouring fast units cervical propriospinal neurones, 477, 479 presynaptic inhibition of Ia terminals, 348 changes in spinal pathways related to the speed of the movement presynaptic inhibition of Ia terminals, 358, 359, 518 recurrent inhibition, 174, 518 spinal cord lesions, clinical features contribution of spasticity to motor impairment, 559, 574, 580 from spinal shock to spasticity, 581-2 therapeutic issues, 580 spinal cord lesions, transmission in spinal pathways at rest, 580 - 1 α motoneurone excitability, 580 F wave, 580 H reflex, 580 plateau potentials, 580 cutaneous reflexes abolition of normal responses, 433 Babinski response, 433-4 cutaneomuscular responses, 423, 436, 437 early withdrawal reflexes, 433, 434 flexor spasms, 434-5 late withdrawal reflexes, 407-10 fusimotor drive, 140, 580 positive feedback through group II projections, 140, 325, reflex activation of γ motoneurones, 140, 580

group II excitation, 322, 581 changes in group I-group II excitation, 322 effect of: clonidine, 322; DOPA, 322 positive feedback via excitation of γ motoneurones, 567–8, 581 underlying mechanisms, 324, 581 lumbar propriospinal pathways, 503, 581; underlying mechanisms, 581 Ib excitation to antagonists, 277, 581; underlying mechanisms, 278, 581 Ib inhibition, 276, 277, 581 post-activation depression, 100, 580 multiple sclerosis, 99 trauma, 99 underlying mechanisms, 99-100, 572 presynaptic inhibition of Ia terminals, 369, 580; underlying mechanisms, 370, 580 reciprocal Ia inhibition, 230 correlation with recovery, 232 focal lesions, distribution, 581 multiple sclerosis, 581 recurrent inhibition, 581 progressive paraparesis: amyotrophic lateral sclerosis, 184, 581; hereditary spastic paraparesis, 186, 581 spinal cord injury, 184, 581 underlying mechanisms, 186, 581 spinal transection, 433 Babinski response, 433 flexor spasms, 434-5 from spinal shock to spasticity, 433 late withdrawal reflexes, 407-10 see also spinal cord lesions spino-bulbo-spinal pathways, 424 standing, 535-42, see perturbations to stance, quiet stance, unstable stance startle response, 424 stimulus rate, see repetition rate strategies for distal and proximal movements, 521-2 stretch reflex (early spinal response, M1) during co-contraction of antagonists: ball joints, 534-5; hinge ioints, 534 functional role in, 87-90: hopping, 87-8; landing, 88-9; running, 87; standing, 89-90, 537; walking (ankle), 89, 548, 549 Ia origin, 87, 293, 320 Ib inhibition reversed during locomotion: cat, 66, 248; humans, 273-5 overlap with group II excitation, 3, 301

636 Index

stretch reflex (cont.) perturbations to stance, 313, 539; function, 320, 540 - 1quiet stance, 364, 537 prevention of stretch reflex during voluntary contraction of the antagonist, 180, 223, 273, 361, 519, 520, 525 sensitivity to presynaptic inhibition of Ia fibres, 354-5 walking: soleus, depending on stretch velocity, 89, 317, 548; despite presynaptic inhibition, 89, 548; tibialis anterior, 548 see also parkinsonian rigidity, spasticity, stroke stroke, clinical features changes in properties of muscle fibres, 573 contracture, 557, 560, 572 contribution to motor impairment, 559, 573 incidence of spasticity, 575 stretch reflex in: elbow muscles, 559; triceps surae, 559, 573 tonic stretch reflex, 557, 575-6 stroke, transmission in spinal pathways at rest, 576-7 α motoneurone excitability, 576 F wave, 576 H reflex: FCR, 576; soleus, 576 cervical propriospinal neurones, 481-4, 579 asymmetry, 481-3 changes throughout recovery, 484 increased transmission of the descending command, 483, 579 methodology, 481 spasticity, 579 synkinetic contractions, 484, 579 underlying mechanisms, 483-4, 579 cutaneous reflexes abolition of normal responses, 433 Babinski response, 433-4 cutaneomuscular responses, 423, 436, 437 withdrawal reflexes, 434 fusimotor drive, 139-40 contribution to motor deficit, 139, 140, 565 γ activity, 139, 576 group II excitation (affected side), 322, 577 effect of tizanidine, 322 underlying mechanisms, 322-4, 577 lumbar propriospinal neurones, 503, 577; underlying mechanisms, 503, 577 non-reciprocal group I inhibition (wrist), 234, 577; correlation with spasticity, 577 Ib excitation to antagonists, 277, 577; underlying mechanisms, 278, 577 Ib inhibition, 276, 577

correlation with spasticity, 276 underlying mechanisms, 277, 577 post-activation depression (affected side), 99, 100, 577; underlying mechanisms, 99-100, 572 presynaptic inhibition of Ia terminals, 368-9, 576 lower limb, 368-9, 576 upper limb, 369, 576 underlying mechanisms, 369-70, 576 reciprocal Ia inhibition, 230, 577 correlation with recovery, 232, 577 underlying mechanisms, 577 recurrent inhibition, 184, 577; underlying mechanisms, 186 stroke, unaffected side, 577-9 abnormal transmission in spinal pathways, 577-9 presynaptic inhibition of Ia terminals, upper limb, 579 reciprocal Ia inhibition, 230, 278, 579 responses to stretch, 577-9 normal transmission in spinal pathways, 579 group II excitation, 322 lumbar propriospinal excitation, 503, 579 Ib excitation, 278, 579 Ib inhibition, 276, 579 post-activation depression, 99, 579 underlying mechanisms, 579 stumbling reaction during locomotion, 387 subliminal excitation of motoneurones created by a conditioning Ia volley, 154, 257 subliminal fringe of excitation of the monosynaptic reflex, 3, 4 synergies see co-ordinated activation of various synergies synergies at wrist level clenching, 211-12, 525 wrist abduction, 211, 522 synkinetic contractions clinical features, 557 pathophysiology, 484, 579 tendon jerk comparison with the H reflex, 117-18 delay with respect to H reflex, 9 differences: in the afferent volleys, 2-3, 117-18; at the motoneurone pool, 118 used as a measure of γ drive, 9, 117 general features pathway, 2, 64 possible propriospinal contribution, 324 reflex irradiation, 96, 131 use to evoke recurrent inhibition, 162

More information

effects of noxious stimuli at knee level, 404-5 spinal pathways at elbow level, 8: cervical propriospinal excitation, 474; Ib excitation, 255; reciprocal Ia inhibition, 201 tendon tap use to distinguish between Ia and Ib effects, 252-3, 255 use to support the Ia origin of group I excitation, 67, 75-6 reciprocal Ia inhibition, 204 termination of movement, spinal mechanisms contributing to, 518 cutaneous inhibition of cervical propriospinal neurones, 478, 518 facilitation of Ib interneurones cutaneous afferents, 262, 271-2, 518 joint afferents, 263, 272, 518 multiple convergence, 265-7 recurrent inhibition not involved, 176 thixotropy, 124-6 advantages, limitations, perspectives, 126 underlying principles, 124 used to study fusimotor activation, 124-5 threshold cervical propriospinal excitation, 460 cutaneomuscular spinal responses, 415 feedback inhibition of cervical propriospinal neurones, 464 group II excitation, 293, 295, 297 lumbar propriospinal excitation, 491 monosynaptic Ia excitation, 64, 67-9, 75 Ib inhibition, 252 presynaptic inhibition (D1), 350 reciprocal Ia inhibition, 204 recurrent inhibition, 166, 171, 206 withdrawal RIII reflex, 400 threshold to electrical stimulation Aß cutaneous afferents, 400, 418 Aδ cutaneous afferents, 400 group Ia afferents, 64, 67-9, 75, 204, 303 activity-dependent hyperpolarisation, 341 elevation by tendon vibration, 76, 205, 245, 260 - 1in the inferior soleus nerve, 69 large range in human experiments, 77-8 with respect to motor threshold, 81 group Ib afferents, 245, 252, 258 group II afferents, 289, 293, 295, 297 group II/Ia ratio, 289, 303 threshold tracking

H reflex, 11, 12 unitary H reflex, 37 timing of changes in spinal pathways during co-contractions of antagonists movement in progress: recurrent inhibition, 180 onset: presynaptic inhibition of Ia terminals, 361; reciprocal Ia inhibition, 225; recurrent inhibition, 180 period preceding contraction: presynaptic inhibition, 361 timing of changes in spinal pathways to active motoneurones during movement, 520-1 movement in progress development of force, 521 fusimotor drive, 135 presynaptic inhibition, 358 recurrent inhibition, 174 onset, 520–1 cervical propriospinal pathways, 474-5 fusimotor drive, 133, 521 Ib inhibition, 270, 521 presynaptic inhibition, 355, 520 recurrent inhibition, 174, 520 period preceding contraction fusimotor drive, 133 Ib inhibition, 270 presynaptic inhibition of Ia terminals, 358 recurrent inhibition, 174 slowing eccentric contractions, 521 fusimotor drive, 521 recruitment order of motoneurones, 519 termination, 518, 521 cutaneous inhibition of cervical propriospinal neurones, 478,518 facilitation of Ib inhibition: cutaneous afferents, 272, 518; joint afferents, 272, 518 recurrent inhibition not involved, 176 timing of changes in spinal pathways to antagonistic motoneurones during movement movement in progress presynaptic inhibition, 360-1 reciprocal Ia inhibition, 221 recurrent inhibition, 180 onset presynaptic inhibition, 360 reciprocal Ia inhibition, 221 recurrent inhibition, 180 period preceding contraction presynaptic inhibition of Ia terminals, 360 reciprocal Ia inhibition, 221 see also relaxation of antagonists

638 Index

tizanidine used to depress group II excitation cat. 292 normal subjects, 294, 299; walking, 317, 318 stroke patients, 322, 323 tonic contractions co-contraction of antagonists fusimotor drive, 135, 532 presynaptic inhibition of Ia terminals, 361, 532 reciprocal Ia inhibition, 225 recurrent inhibition, 180 contraction of the antagonistic muscle Ib inhibition, 273, 520 presynaptic inhibition of Ia terminals, 361 reciprocal Ia inhibition, 219-23 recurrent inhibition, 180 contraction of the target muscle, 512-15 cervical propriospinal pathways, 476-7 cutaneomuscular responses, 514 fusimotor drive, 122, 133, 512 group II excitation, 310-12 lumbar propriospinal neurones, 500-2 Ib inhibition, 268, 271, 515 post-activation depression, 99 presynaptic inhibition of Ia terminals, 358 reciprocal Ia inhibition, 223 recurrent inhibition, 174 transcortical cutaneous pathways afferent pathway, 421 central pathway, 421-4 evidence for transcortical mediation, 422, 424 latency, 421-3: calculations, 421-2, 423; rostrocaudal sequence, 421 observations in patients, 423 possible contribution of other pathways, 424 E2 excitatory cutaneomuscular responses lower limb, 415, 416 upper limb, 415, 417 I1 inhibitory cutaneomuscular response, 415, 417 evidence for transcortical mediation, 423 possible function, 428 maturation, 423, 428 motor task-related changes hopping, 432 voluntary contractions, 427, 428, 429 walking, 430-2: evidence for transcortical mediation, 430-1, 432; flexor muscles, 430, 431; functional role, 432, 549-50; pattern and timing, 430, 549; reflex reversal, 430 Parkinson's disease, 437 upper motoneurone lesions, 423, 436, 437

transcortical group II pathways Parkinson's disease, 584 standing, in the antagonist of the stretched muscle, 540; significance, 541 transcortical Ia pathways hand muscles, 90, 92; functional significance, 92 history, 90-1 interaction with voluntary intent, 92, 539 lower limb, 91-2 functional stretch reflex, 91, 539 voluntary contraction, 548 walking, 548-9: in soleus, 548; in tibialis anterior, 548-9; role, 549-50; upper motoneurone lesions, 548, 549 Parkinson's disease, 583, 584 transcranial magnetic stimulation (TMS), see cortical stimulation tremor, see parkinsonian tremor trisynaptic effects disfacilitation of propriospinal neurones, 467 Ib excitation, 255 trunk skin reflexes central delay, 400 changes during voluntary contraction, 412 reciprocal organisation, 402 upper motoneurone diseases, 433 see also abdominal skin reflexes unaffected side in hemiplegia, see stroke, unaffected side, 577-9 unitary H reflex, 37-9 general features advantages, 39 limitations, 39 underlying principles, 37, 38 methodology basic methodology, 37 critical firing stimulus and its significance, 37, 38-9 recording, 37 stimulation, 37-8 threshold tracking, 37 used to study presynaptic inhibition of Ia terminals (heteronymous Ia

facilitation), 38-9, 347

antagonists, 219

single units at rest, 37

voluntary contraction, 133 walking, unloading soleus, 315–16

unloading

reciprocal Ia inhibition during contraction of the

skewed distribution of corticospinal inputs at rest, 45

Index 639

EMG suppression, 315-16 methodology, 315 unstable stance co-contraction of synergists, 94, 537-8 cutaneomuscular responses, 430, 514 fusimotor drive, 135, 538 homonymous Ia and group II excitation, 38 heteronymous group II excitation, 313-14, 538 focus, 538 function, 314, 538 leaning: backwards, 313-14; forwards, 314 underlying mechanisms, 314, 538 heteronymous Ia excitation, 94, 538; focus, 183, 538 reciprocal Ia inhibition, 227 updating of the descending command, 454, 477, 529 upper motoneurone lesion, changes in α motoneurone excitability, 560-3 cervical propriospinal pathways, 481-4, 579 cutaneous reflexes, 433-6 abolition of normal responses, 433 Babinski response, 433-4 cutaneomuscular responses, 423, 436, 437 withdrawal reflexes, 434-5 fusimotor drive, 139-40, 563-5 group II excitation, 320-6, 567-8 lumbar propriospinal pathways, 503, 566-7 non-reciprocal group I inhibition (wrist), 234 Ib excitation, 277, 569 Ib inhibition, 276, 568-9 post-activation depression, 99-100, 566 presynaptic inhibition of Ia terminals, 368-70, 565-6 reciprocal Ia inhibition, 229-33, 570 recurrent inhibition, 184-7, 569 transcortical group I pathways, 548, 549 transcortical cutaneous pathways, 423 withdrawal reflexes, 434-5 upper motoneurone syndrome, 557 loss of dexterity, 557 negative symptoms, 557 positive symptoms, 557; reflex release, 557 release of flexor reflexes, 434-5, 557 spasticity, 557 weakness, 557 reciprocal inhibition from the stretched muscle, 574 spindle behaviour, 139, 140, 565 unaffected side, 579

vestibulospinal control, background from animal experiments group II interneurones, 292 lumbar propriospinal neurones, 491 la interneurones, 200 PAD interneurones, 339 vestibulospinal projections Ia interneurones, 216-17 Ib interneurones, 265 PAD interneurones, 353, 364 Renshaw cells, 181 vibration of the homonymous tendon activation of, 130-1 cutaneous mechanoreceptors, 131 Golgi tendon organs, 123, 130-1 primary endings, 130, 132 secondary endings, 130, 132 spindle endings during contraction, 131 activity-dependent hyperpolarisation of Ia afferents, 12-13, 341 post-activation depression at the Ia-motoneurone synapse, 341, 368, 371, 565 presynaptic inhibition of Ia terminals, 341 vibration paradox, 341 vibration, used to produce activation of primary endings in cats, 64, 114 humans, 130, 132 elevation of the electrical threshold of Ia afferents, 76, 205, 245, 260-1 presynaptic inhibition of Ia terminals heteronymous, 341-2 homonymous, 341 voluntary co-contraction of antagonists, 531-5 changes in spinal pathways to antagonists, 531-2 fusimotor drive, 135, 532 non-reciprocal group I inhibition (wrist), 523, 532 presynaptic inhibition of Ia terminals: ankle, 361, 532; wrist, 523, 532 reciprocal Ia inhibition (ankle), 225-7, 531 recurrent inhibition: ankle, 177, 180, 531-2; wrist, 523, 534 control of motor output and recurrent inhibition: hinge joints, 532; wrist, 534 joint stiffness, 533-4 pathways involved in co-contraction of antagonists cervical propriospinal relay, 533 corticospinal drive, 225-6, 533 spinal pathways, 533 stretch reflex: hinge joints, 534; wrist, 534-5

640 Index

voluntary contraction, see concentric and eccentric contractions; force, speed of movement: onset, termination, timing of movement; ramp and tonic voluntary contractions; relaxation of antagonists; voluntary co-contraction; voluntary contraction of antagonist, remote, synergist, target muscles: voluntary movement voluntary contraction of antagonists changes in pathways to inactive antagonists, 519-20 non-reciprocal group I inhibition (wrist), 524-5 Ib inhibition (ankle), 273, 520 presynaptic inhibition of Ia terminals: lower limb, 360-1, 519; wrist, 363, 526 propriospinally mediated inhibition of motoneurones, 217-19, 503, 519-20 reciprocal Ia inhibition, 217-3, 519 recurrent inhibition, 180, 520 spindle activation, 135, 221-2 functional significance of changes in spinal pathways non-reciprocal group I inhibition (wrist), 525-6 Ib inhibition (ankle), 273, 520 presynaptic inhibition of Ia terminals, 361 propriospinally mediated inhibition of motoneurones, 503, 520 reciprocal Ia inhibition on: motoneurones, 223, 520; opposite Ia interneurones, 222, 223, 520 recurrent inhibition (ankle), 180, 520 spindle activation, 137-8 voluntary contraction of remote muscles (Jendrassik manoeuvre) central changes in the gain of the reflex, 133, 134 fusimotor drive, 131; flawed hypothesis, 131-2 presynaptic inhibition of Ia terminals, 133, 361-2 reciprocal Ia inhibition, 133, 227 voluntary contraction of synergistic muscles changes in pathways to inactive synergists fusimotor drive, 135 Ib inhibition, 273, 517 presynaptic inhibition of Ia terminals, 359-60 recurrent inhibition, 183 focus on contracting muscles cervical propriospinal neurones, 476, 477, 517 fusimotor drive, 517 Ib inhibition, 273, 517 presynaptic inhibition of Ia terminals, 359-60, 517, 529 recurrent inhibition, 183-4, 529, 538

voluntary contraction of the target muscle changes in spinal pathways to active muscles, 513, 516 - 17cervical propriospinal neurones, 471-9 cutaneomuscular responses, 427-30, 514 fusimotor drive, 133-6, 512-14, 516 group II excitation, 310-12 lumbar propriospinal neurones, 500-2 non-reciprocal group I inhibition (wrist), 523, 524 Ib inhibition, 268-71, 515, 517; facilitation by other afferents, 271-2, 515 post-activation depression, 99 presynaptic inhibition of Ia terminals: lower limb, 355-8; wrist, 362-3, 526 reciprocal Ia inhibition, 223-5, 517 recurrent inhibition, 173-9, 514-15, 517 withdrawal reflexes, 412-14 functional significance of changes in spinal pathways cervical propriospinal excitation, 477-8, 516-17, 529 feedback inhibition of cervical propriospinal neurones: cutaneous, 478, 518; group I, 477, 517, 518 fusimotor drive, 136-8, 512; slowing eccentric contractions, 521 group II excitation, 312, 514 lumbar propriospinal excitation, 502-3 non-reciprocal group I inhibition (wrist), 523, 525-6 Ib inhibition, 271, 517, 518; facilitation by other afferents, 272.515 presynaptic inhibition of Ia terminals, 359, 517, 518 reciprocal Ia inhibition, 225, 518 recurrent inhibition, 179, 517, 518 voluntary movement, control of different features co-ordinated synergies, 527-1 force and speed, 359, 517-18 inhibition of antagonists: hinge joints, 513, 519-20; wrist, 523, 525-6 pathways to active motoneurones, 513, 516-17; excitatory, 516-17; inhibitory, 517 recruitment of different motoneurone types, 518-19 selectivity, 517 strategies for distal and proximal movements, 521-2 termination, 518 timing, 520-1 tonic contraction vs. movement, 522 walking, characteristics of human gait, 542-4

biomechanical characteristics of number gail, 542–4 different roles of ankle and knee extensors, 273–4 lengthening loaded contractions, 544

Index 641

pattern of muscle activation, 543, 544 use of external energy, 544 walking, changes in spinal and transcortical pathways fusimotor drive, 137, 544 group II excitation, 545-6 quadriceps (heteronymous), 318, 546 soleus (homonymous), 315-16, 545-6 monosynaptic Ia excitation of soleus Ib inhibition, 274, 546 heteronymous, 93 homonymous, 89 stretch reflex, 89 presynaptic inhibition of quadriceps Ia terminals, 365, 545 soleus Ia terminals, 365-6, 545 reciprocal Ia inhibition (ankle), 227-9, 546 recurrent inhibition (knee), 546 stretch responses in soleus group II, 316-18, 548 monosynaptic Ia, 89, 548 transcortical, 548 stretch responses in tibialis anterior group II, 316, 318, 548 monosynaptic Ia, 548 transcortical, 548-9 transcortical cutaneous responses, 430-2, 549 evidence for, 430-2 pattern and timing, 430, 549 reflex reversal, 430 walking, role of spinal pathways contribution to soleus activation, 319-20, 545-6 cutaneous facilitation of reciprocal Ia inhibition, 214-15, 549 prevention of excessive Ia activity in soleus, 546-7 Ib inhibition, 274, 546-7 pattern of Ia projections, 93, 546 presynaptic inhibition, 366-7, 546 propriospinally mediated inhibition of motoneurones, 503, 547 stabilisation of the ankle heteronymous Ia projections, 93, 546 reciprocal Ia inhibition, 229, 546 stretch responses, 318, 546, 549 stabilisation of the knee cutaneous suppression of Ib inhibition to quadriceps, 274, 547 group I-II discharge from tibialis anterior, 319, 547 heteronymous Ib effects to biceps, 274-5, 547 presynaptic inhibition, 365, 547 recurrent inhibition, 547

stumbling, 94, 548 transition, 547 yield of the knee, 365, 547 walking, role of transcortical pathways cutaneous pathways, 432, 549-50 group I pathways, 549-50 stretch responses in ankle muscles, 549 walking, studies in patients with upper motoneurone lesions presynaptic inhibition of Ia terminals, 370-1, 575 transcortical group I excitation, 548, 549 withdrawal reflexes, 435 weakness, see upper motoneurone syndrome withdrawal reflexes, background from animal experiments FRA pathways, 388-91: early, 389-90; late, 390-1 initial findings, 385 private pathways of withdrawal reflexes, 387 crossed extension reflex, 385 extensor activation, 387 flexor reflex, 385, 387 modular organisation, 386, 387 withdrawal reflexes, methodology critique of tests, 396-8 stimuli effects on late responses of increased stimulus intensity or duration in: normal subjects, 410; patients with spinal transection, 408 electrical, 392 mechanical, 392, 394 modulation of motoneurone excitability, 396 monosynaptic reflexes, 396; on-going EMG, 396 reflexes at rest: RIII in the biceps femoris, 394; other withdrawal reflexes, 394, 395 withdrawal reflexes, organisation, 399-414 afferent pathway of the RIII reflex, 399-400 afferents: Aβ, 400; Aδ, 400 pain sensation, 399-400: nerve, 399; skin, 399-400 central pathway, 400-1: central delay, 400-1; complete spinal transection, 401 conditioning by afferents, 411-12 nociceptive afferents, 411: early facilitation, 393, 411; late depression, 395, 411; underlying mechanisms, 411 tactile afferents, 393, 411-12; underlying mechanisms, 412 warmth, 412 descending effects early FRAs, 412; abdominal skin reflexes, 433; plantar response, 434 late FRAs in normal subjects, 411 functional organisation, 401-7 convergence of tactile afferents, 402, 405

642 Index

withdrawal reflexes, organisation (cont.) local sign, 397, 402-3, 404-5, 407 modular organisation, 407 lower limb responses, 404-5: afferent pathway, 401; central delay, 401; modulation of monosynaptic reflexes, 397, 404-5; receptive fields, 397, 404-5 plantar responses, 402-4: extensor hallucis longus, 402; maturation, 404; receptive fields, 402-4 trunk muscles, 402 upper limb responses, 405-7: central delay, 401, 405; evidence for motoneurone inhibition, 405, 406; responses at rest, 405-6, 407; silent period, 405, 406 protective function, 399, 401-2, 404, 405, 406, 407 rIII reflex in the biceps femoris: afferent pathway, 400; central pathway, 401; pain sensation, 399-400; threshold, 400 reciprocal organisation, 397, 402, 404, 405 withdrawal reflexes (late) in normal subjects, 397, 410-11 characteristics, 410: latency, 410; threshold, 410 plasticity, influence of, 410: continuous stimulation, 410; hypnosis, 410; posture, 410 supraspinal mediation, 411 withdrawal reflexes, physiological implications postural tasks, 413, 414 voluntary contraction, 412-14 leg muscles, 412-13, 414 trunk muscles, 412 withdrawal reflexes, studies in patients Babinski response, 403, 434 complete spinal transection, 433

Parkinson's disease, 436-7, 589 peripheral neuropathies, 437 upper motoneurone lesions, lower limb, 434-5 alterations of withdrawal reflexes, 434 extensor inhibition, 435 flexor spasms, 434-5 plantar nerve stimulation, 435 walking, 435 upper motoneurone lesions, upper limb, 435 withdrawal reflexes (late), patients with spinal transection, 407 - 10background from animal experiments, 390-1 characteristics effects of increased stimulus intensity or duration, 408, 409 inhibition from contralateral FRAs, 408, 409 inhibition from early FRAs, 408, 410 long-latency ipsilateral flexion, 407-8 contralateral effects, 408, 409 post-synaptic facilitation of extensors, 408 presynaptic inhibition of Ia terminals, 408 contribution of high-threshold muscle afferents, 433 evidence for spinal reflexes, 407 from spinal shock to spasticity, 433 larger receptive field, 433 methodology, 407, 433 wrist, see organisation of spinal circuitry at wrist level

yield of the knee, 365, 547